Keywords
Last Name
Institution

Kenneth L. Davis

Address1425 Madison Avenue
New York NY 10029
Phone212-659-8888
Fax212-659-9800

     Bibliographic 
     selected publications
    Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Faculty can login to make corrections and additions.
    List All   |   Timeline
    1. Roussos P, Katsel P, Davis KL, Siever LJ, Haroutunian V. A system-level transcriptomic analysis of schizophrenia using postmortem brain tissue samples. Arch Gen Psychiatry. 2012 Dec; 69(12):1205-13.
      View in: PubMed
    2. Roussos P, Katsel P, Davis KL, Giakoumaki SG, Lencz T, Malhotra AK, Siever LJ, Bitsios P, Haroutunian V. Convergent findings for abnormalities of the NF-?B signaling pathway in schizophrenia. Neuropsychopharmacology. 2013 Feb; 38(3):533-9.
      View in: PubMed
    3. Roussos P, Katsel P, Davis KL, Bitsios P, Giakoumaki SG, Jogia J, Rozsnyai K, Collier D, Frangou S, Siever LJ, Haroutunian V. Molecular and genetic evidence for abnormalities in the nodes of Ranvier in schizophrenia. Arch Gen Psychiatry. 2012 Jan; 69(1):7-15.
      View in: PubMed
    4. Tang CY, Friedman JI, Carpenter DM, Novakovic V, Eaves E, Ng J, Wu YW, Gottlieb S, Wallenstein S, Moshier E, Parrella M, White L, Bowler S, McGinn TG, Flanagan L, Davis KL. The effects of hypertension and body mass index on diffusion tensor imaging in schizophrenia. Schizophr Res. 2011 Aug; 130(1-3):94-100.
      View in: PubMed
    5. Katsel P, Tan W, Abazyan B, Davis KL, Ross C, Pletnikov MV, Haroutunian V. Expression of mutant human DISC1 in mice supports abnormalities in differentiation of oligodendrocytes. Schizophr Res. 2011 Aug; 130(1-3):238-49.
      View in: PubMed
    6. Takahashi N, Sakurai T, Bozdagi-Gunal O, Dorr NP, Moy J, Krug L, Gama-Sosa M, Elder GA, Koch RJ, Walker RH, Hof PR, Davis KL, Buxbaum JD. Increased expression of receptor phosphotyrosine phosphatase-ß/? is associated with molecular, cellular, behavioral and cognitive schizophrenia phenotypes. Transl Psychiatry. 2011; 1:e8.
      View in: PubMed
    7. Davis KL, Panksepp J. The brain's emotional foundations of human personality and the Affective Neuroscience Personality Scales. Neurosci Biobehav Rev. 2011 Oct; 35(9):1946-58.
      View in: PubMed
    8. Friedman JI, Lindenmayer JP, Alcantara F, Bowler S, Parak M, White L, Iskander A, Parrella M, Adler DN, Tsopelas ND, Tsai WY, Novakovic V, Novakovick V, Harvey PD, Davis KL, Kaushik S. Pimozide augmentation of clozapine inpatients with schizophrenia and schizoaffective disorder unresponsive to clozapine monotherapy. Neuropsychopharmacology. 2011 May; 36(6):1289-95.
      View in: PubMed
    9. Radu A, Hristescu G, Katsel P, Haroutunian V, Davis KL. Microarray database mining and cell differentiation defects in schizophrenia. Adv Exp Med Biol. 2011; 696:67-74.
      View in: PubMed
    10. Davis K. Commentary: What happens when a combined entity is lesser than the sum of its parts? Acad Med. 2010 Dec; 85(12):1815-6.
      View in: PubMed
    11. Takahashi N, Sakurai T, Davis KL, Buxbaum JD. Linking oligodendrocyte and myelin dysfunction to neurocircuitry abnormalities in schizophrenia. Prog Neurobiol. 2011 Jan; 93(1):13-24.
      View in: PubMed
    12. Friedman JI, Wallenstein S, Moshier E, Parrella M, White L, Bowler S, Gottlieb S, Harvey PD, McGinn TG, Flanagan L, Davis KL. The effects of hypertension and body mass index on cognition in schizophrenia. Am J Psychiatry. 2010 Oct; 167(10):1232-9.
      View in: PubMed
    13. Glessner JT, Reilly MP, Kim CE, Takahashi N, Albano A, Hou C, Bradfield JP, Zhang H, Sleiman PM, Flory JH, Imielinski M, Frackelton EC, Chiavacci R, Thomas KA, Garris M, Otieno FG, Davidson M, Weiser M, Reichenberg A, Davis KL, Friedman JI, Cappola TP, Margulies KB, Rader DJ, Grant SF, Buxbaum JD, Gur RE, Hakonarson H. Strong synaptic transmission impact by copy number variations in schizophrenia. Proc Natl Acad Sci U S A. 2010 Jun 8; 107(23):10584-9.
      View in: PubMed
    14. Barnes SL, Robinson BR, Richards JT, Zimmerman CE, Pritts TA, Tsuei BJ, Butler KL, Muskat PC, Davis K, Johannigman JA. The devil is in the details: maximizing revenue for daily trauma care. Surgery. 2008 Oct; 144(4):670-5; discussion 675-6.
      View in: PubMed
    15. Carpenter DM, Tang CY, Friedman JI, Hof PR, Stewart DG, Buchsbaum MS, Harvey PD, Gorman JG, Davis KL. Temporal characteristics of tract-specific anisotropy abnormalities in schizophrenia. Neuroreport. 2008 Sep 17; 19(14):1369-72.
      View in: PubMed
    16. Friedman JI, Tang C, Carpenter D, Buchsbaum M, Schmeidler J, Flanagan L, Golembo S, Kanellopoulou I, Ng J, Hof PR, Harvey PD, Tsopelas ND, Stewart D, Davis KL. Diffusion tensor imaging findings in first-episode and chronic schizophrenia patients. Am J Psychiatry. 2008 Aug; 165(8):1024-32.
      View in: PubMed
    17. Stewart DG, Davis KL. The lobotomist. Am J Psychiatry. 2008 Apr; 165(4):457-8.
      View in: PubMed
    18. Katsel P, Davis KL, Li C, Tan W, Greenstein E, Kleiner Hoffman LB, Haroutunian V. Abnormal indices of cell cycle activity in schizophrenia and their potential association with oligodendrocytes. Neuropsychopharmacology. 2008 Nov; 33(12):2993-3009.
      View in: PubMed
    19. Friedman JI, Davis KL, Chang L, Ernst T, Tsopelas ND, Zhong K. Relationships between white matter metabolite abnormalities, cognitive and social functioning in elderly schizophrenic subjects. Schizophr Res. 2008 Mar; 100(1-3):356-8.
      View in: PubMed
    20. Byne W, Dracheva S, Chin B, Schmeidler JM, Davis KL, Haroutunian V. Schizophrenia and sex associated differences in the expression of neuronal and oligodendrocyte-specific genes in individual thalamic nuclei. Schizophr Res. 2008 Jan; 98(1-3):118-28.
      View in: PubMed
    21. Haroutunian V, Davis KL. Introduction to the special section: Myelin and oligodendrocyte abnormalities in schizophrenia. Int J Neuropsychopharmacol. 2007 Aug; 10(4):499-502.
      View in: PubMed
    22. Friedman JI, Vrijenhoek T, Markx S, Janssen IM, van der Vliet WA, Faas BH, Knoers NV, Cahn W, Kahn RS, Edelmann L, Davis KL, Silverman JM, Brunner HG, van Kessel AG, Wijmenga C, Ophoff RA, Veltman JA. CNTNAP2 gene dosage variation is associated with schizophrenia and epilepsy. Mol Psychiatry. 2008 Mar; 13(3):261-6.
      View in: PubMed
    23. Tang CY, Friedman J, Shungu D, Chang L, Ernst T, Stewart D, Hajianpour A, Carpenter D, Ng J, Mao X, Hof PR, Buchsbaum MS, Davis K, Gorman JM. Correlations between Diffusion Tensor Imaging (DTI) and Magnetic Resonance Spectroscopy (1H MRS) in schizophrenic patients and normal controls. BMC Psychiatry. 2007; 7:25.
      View in: PubMed
    24. Buxbaum JD, Georgieva L, Young JJ, Plescia C, Kajiwara Y, Jiang Y, Moskvina V, Norton N, Peirce T, Williams H, Craddock NJ, Carroll L, Corfas G, Davis KL, Owen MJ, Harroch S, Sakurai T, O'Donovan MC. Molecular dissection of NRG1-ERBB4 signaling implicates PTPRZ1 as a potential schizophrenia susceptibility gene. Mol Psychiatry. 2008 Feb; 13(2):162-72.
      View in: PubMed
    25. Mapping autism risk loci using genetic linkage and chromosomal rearrangements. Nat Genet. 2007 Mar; 39(3):319-28.
      View in: PubMed
    26. Haroutunian V, Katsel P, Dracheva S, Stewart DG, Davis KL. Variations in oligodendrocyte-related gene expression across multiple cortical regions: implications for the pathophysiology of schizophrenia. Int J Neuropsychopharmacol. 2007 Aug; 10(4):565-73.
      View in: PubMed
    27. McCullumsmith RE, Gupta D, Beneyto M, Kreger E, Haroutunian V, Davis KL, Meador-Woodruff JH. Expression of transcripts for myelination-related genes in the anterior cingulate cortex in schizophrenia. Schizophr Res. 2007 Feb; 90(1-3):15-27.
      View in: PubMed
    28. Branson RD, Davis K, Butler KL. African Americans' participation in clinical research: importance, barriers, and solutions. Am J Surg. 2007 Jan; 193(1):32-9; discussion 40.
      View in: PubMed
    29. Haroutunian V, Katsel P, Dracheva S, Davis KL. The human homolog of the QKI gene affected in the severe dysmyelination "quaking" mouse phenotype: downregulated in multiple brain regions in schizophrenia. Am J Psychiatry. 2006 Oct; 163(10):1834-7.
      View in: PubMed
    30. Friedman JI, Davis KL. Special issue: Molecular mechanisms of schizophrenia. Biol Psychiatry. 2006 Sep 15; 60(6):527-9.
      View in: PubMed
    31. White L, Friedman JI, Bowie CR, Evers M, Harvey PD, Parrella M, Mihaila E, Davis KL. Long-term outcomes in chronically hospitalized geriatric patients with schizophrenia: retrospective comparison of first generation and second generation antipsychotics. Schizophr Res. 2006 Dec; 88(1-3):127-34.
      View in: PubMed
    32. Buchsbaum MS, Friedman J, Buchsbaum BR, Chu KW, Hazlett EA, Newmark R, Schneiderman JS, Torosjan Y, Tang C, Hof PR, Stewart D, Davis KL, Gorman J. Diffusion tensor imaging in schizophrenia. Biol Psychiatry. 2006 Dec 1; 60(11):1181-7.
      View in: PubMed
    33. Georgieva L, Moskvina V, Peirce T, Norton N, Bray NJ, Jones L, Holmans P, Macgregor S, Zammit S, Wilkinson J, Williams H, Nikolov I, Williams N, Ivanov D, Davis KL, Haroutunian V, Buxbaum JD, Craddock N, Kirov G, Owen MJ, O'Donovan MC. Convergent evidence that oligodendrocyte lineage transcription factor 2 (OLIG2) and interacting genes influence susceptibility to schizophrenia. Proc Natl Acad Sci U S A. 2006 Aug 15; 103(33):12469-74.
      View in: PubMed
    34. Gill SK, Ishak M, Dobransky T, Haroutunian V, Davis KL, Rylett RJ. 82-kDa choline acetyltransferase is in nuclei of cholinergic neurons in human CNS and altered in aging and Alzheimer disease. Neurobiol Aging. 2007 Jul; 28(7):1028-40.
      View in: PubMed
    35. Carrión-Baralt JR, Smith CJ, Rossy-Fullana E, Lewis-Fernández R, Davis KL, Silverman JM. Seasonality effects on schizophrenic births in multiplex families in a tropical island. Psychiatry Res. 2006 May 30; 142(1):93-7.
      View in: PubMed
    36. Harvey PD, Friedman JI, Bowie C, Reichenberg A, McGurk SR, Parrella M, White L, Davis KL. Validity and stability of performance-based estimates of premorbid educational functioning in older patients with schizophrenia. J Clin Exp Neuropsychol. 2006 Feb; 28(2):178-92.
      View in: PubMed
    37. Prohovnik I, Perl DP, Davis KL, Libow L, Lesser G, Haroutunian V. Dissociation of neuropathology from severity of dementia in late-onset Alzheimer disease. Neurology. 2006 Jan 10; 66(1):49-55.
      View in: PubMed
    38. Dracheva S, Davis KL, Chin B, Woo DA, Schmeidler J, Haroutunian V. Myelin-associated mRNA and protein expression deficits in the anterior cingulate cortex and hippocampus in elderly schizophrenia patients. Neurobiol Dis. 2006 Mar; 21(3):531-40.
      View in: PubMed
    39. Clinton SM, Ibrahim HM, Frey KA, Davis KL, Haroutunian V, Meador-Woodruff JH. Dopaminergic abnormalities in select thalamic nuclei in schizophrenia: involvement of the intracellular signal integrating proteins calcyon and spinophilin. Am J Psychiatry. 2005 Oct; 162(10):1859-71.
      View in: PubMed
    40. Katsel P, Davis KL, Gorman JM, Haroutunian V. Variations in differential gene expression patterns across multiple brain regions in schizophrenia. Schizophr Res. 2005 Sep 15; 77(2-3):241-52.
      View in: PubMed
    41. Gupta DS, McCullumsmith RE, Beneyto M, Haroutunian V, Davis KL, Meador-Woodruff JH. Metabotropic glutamate receptor protein expression in the prefrontal cortex and striatum in schizophrenia. Synapse. 2005 Sep 1; 57(3):123-31.
      View in: PubMed
    42. Katsel P, Davis KL, Haroutunian V. Variations in myelin and oligodendrocyte-related gene expression across multiple brain regions in schizophrenia: a gene ontology study. Schizophr Res. 2005 Nov 15; 79(2-3):157-73.
      View in: PubMed
    43. Bruneau EG, McCullumsmith RE, Haroutunian V, Davis KL, Meador-Woodruff JH. Increased expression of glutaminase and glutamine synthetase mRNA in the thalamus in schizophrenia. Schizophr Res. 2005 Jun 1; 75(1):27-34.
      View in: PubMed
    44. Friedman JI, Ocampo R, Elbaz Z, Parrella M, White L, Bowler S, Davis KL, Harvey PD. The effect of citalopram adjunctive treatment added to atypical antipsychotic medications for cognitive performance in patients with schizophrenia. J Clin Psychopharmacol. 2005 Jun; 25(3):237-42.
      View in: PubMed
    45. Beeri MS, Silverman JM, Davis KL, Marin D, Grossman HZ, Schmeidler J, Purohit DP, Perl DP, Davidson M, Mohs RC, Haroutunian V. Type 2 diabetes is negatively associated with Alzheimer's disease neuropathology. J Gerontol A Biol Sci Med Sci. 2005 Apr; 60(4):471-5.
      View in: PubMed
    46. Katsel PL, Davis KL, Haroutunian V. Large-scale microarray studies of gene expression in multiple regions of the brain in schizophrenia and Alzheimer's disease. Int Rev Neurobiol. 2005; 63:41-82.
      View in: PubMed
    47. Dracheva S, Elhakem SL, McGurk SR, Davis KL, Haroutunian V. GAD67 and GAD65 mRNA and protein expression in cerebrocortical regions of elderly patients with schizophrenia. J Neurosci Res. 2004 May 15; 76(4):581-92.
      View in: PubMed
    48. Taylor RW, Zimmerman JL, Dellinger RP, Straube RC, Criner GJ, Davis K, Kelly KM, Smith TC, Small RJ. Low-dose inhaled nitric oxide in patients with acute lung injury: a randomized controlled trial. JAMA. 2004 Apr 7; 291(13):1603-9.
      View in: PubMed
    49. Ramoz N, Reichert JG, Smith CJ, Silverman JM, Bespalova IN, Davis KL, Buxbaum JD. Linkage and association of the mitochondrial aspartate/glutamate carrier SLC25A12 gene with autism. Am J Psychiatry. 2004 Apr; 161(4):662-9.
      View in: PubMed
    50. McGurk SR, Coleman T, Harvey PD, Reichenberg A, White L, Friedman J, Parrella M, Davis KL. Working memory performance in poor outcome schizophrenia: relationship to age and executive functioning. J Clin Exp Neuropsychol. 2004 Apr; 26(2):153-60.
      View in: PubMed
    51. Bowie CR, Harvey PD, Moriarty PJ, Parrella M, White L, Davis KL. A comprehensive analysis of verbal fluency deficit in geriatric schizophrenia. Arch Clin Neuropsychol. 2004 Mar; 19(2):289-303.
      View in: PubMed
    52. Siever LJ, Davis KL. The pathophysiology of schizophrenia disorders: perspectives from the spectrum. Am J Psychiatry. 2004 Mar; 161(3):398-413.
      View in: PubMed
    53. Mueller HT, Haroutunian V, Davis KL, Meador-Woodruff JH. Expression of the ionotropic glutamate receptor subunits and NMDA receptor-associated intracellular proteins in the substantia nigra in schizophrenia. Brain Res Mol Brain Res. 2004 Feb 5; 121(1-2):60-9.
      View in: PubMed
    54. Stewart DG, Davis KL. Possible contributions of myelin and oligodendrocyte dysfunction to schizophrenia. Int Rev Neurobiol. 2004; 59:381-424.
      View in: PubMed
    55. Bubber P, Tang J, Haroutunian V, Xu H, Davis KL, Blass JP, Gibson GE. Mitochondrial enzymes in schizophrenia. J Mol Neurosci. 2004; 24(2):315-21.
      View in: PubMed
    56. Martin-Ruiz CM, Haroutunian VH, Long P, Young AH, Davis KL, Perry EK, Court JA. Dementia rating and nicotinic receptor expression in the prefrontal cortex in schizophrenia. Biol Psychiatry. 2003 Dec 1; 54(11):1222-33.
      View in: PubMed
    57. Buchsbaum MS, Shihabuddin L, Brickman AM, Miozzo R, Prikryl R, Shaw R, Davis K. Caudate and putamen volumes in good and poor outcome patients with schizophrenia. Schizophr Res. 2003 Nov 1; 64(1):53-62.
      View in: PubMed
    58. Harvey PD, Bertisch H, Friedman JI, Marcus S, Parrella M, White L, Davis KL. The course of functional decline in geriatric patients with schizophrenia: cognitive-functional and clinical symptoms as determinants of change. Am J Geriatr Psychiatry. 2003 Nov-Dec; 11(6):610-9.
      View in: PubMed
    59. Causevic M, Ramoz N, Haroutunian V, Davis KL, Buxbaum JD. Lack of association between the levels of the low-density lipoprotein receptor-related protein (LRP) and either Alzheimer dementia or LRP exon 3 genotype. J Neuropathol Exp Neurol. 2003 Oct; 62(10):999-1005.
      View in: PubMed
    60. Polesskaya OO, Haroutunian V, Davis KL, Hernandez I, Sokolov BP. Novel putative nonprotein-coding RNA gene from 11q14 displays decreased expression in brains of patients with schizophrenia. J Neurosci Res. 2003 Oct 1; 74(1):111-22.
      View in: PubMed
    61. Davis KL, Haroutunian V. Global expression-profiling studies and oligodendrocyte dysfunction in schizophrenia and bipolar disorder. Lancet. 2003 Sep 6; 362(9386):758.
      View in: PubMed
    62. Mathalon DH, Rapoport JL, Davis KL, Krystal JH. Neurotoxicity, neuroplasticity, and magnetic resonance imaging morphometry. Arch Gen Psychiatry. 2003 Aug; 60(8):846-8; author reply 848-9.
      View in: PubMed
    63. Hof PR, Haroutunian V, Friedrich VL, Byne W, Buitron C, Perl DP, Davis KL. Loss and altered spatial distribution of oligodendrocytes in the superior frontal gyrus in schizophrenia. Biol Psychiatry. 2003 Jun 15; 53(12):1075-85.
      View in: PubMed
    64. Aisen PS, Schafer KA, Grundman M, Pfeiffer E, Sano M, Davis KL, Farlow MR, Jin S, Thomas RG, Thal LJ. Effects of rofecoxib or naproxen vs placebo on Alzheimer disease progression: a randomized controlled trial. JAMA. 2003 Jun 4; 289(21):2819-26.
      View in: PubMed
    65. Clinton SM, Haroutunian V, Davis KL, Meador-Woodruff JH. Altered transcript expression of NMDA receptor-associated postsynaptic proteins in the thalamus of subjects with schizophrenia. Am J Psychiatry. 2003 Jun; 160(6):1100-9.
      View in: PubMed
    66. Davis KL, Stewart DG, Friedman JI, Buchsbaum M, Harvey PD, Hof PR, Buxbaum J, Haroutunian V. White matter changes in schizophrenia: evidence for myelin-related dysfunction. Arch Gen Psychiatry. 2003 May; 60(5):443-56.
      View in: PubMed
    67. Serby M, Brickman AM, Haroutunian V, Purohit DP, Marin D, Lantz M, Mohs RC, Davis KL. Cognitive burden and excess Lewy-body pathology in the Lewy-body variant of Alzheimer disease. Am J Geriatr Psychiatry. 2003 May-Jun; 11(3):371-4.
      View in: PubMed
    68. Neugroschl J, Davis KL. Biological markers in Alzheimer disease. Am J Geriatr Psychiatry. 2002 Nov-Dec; 10(6):660-77.
      View in: PubMed
    69. Bowie CR, Harvey PD, Moriarty PJ, Parrella M, White L, Mohs RC, Davis KL. Cognitive assessment of geriatric schizophrenic patients with severe impairment. Arch Clin Neuropsychol. 2002 Oct; 17(7):611-23.
      View in: PubMed
    70. Hof PR, Haroutunian V, Copland C, Davis KL, Buxbaum JD. Molecular and cellular evidence for an oligodendrocyte abnormality in schizophrenia. Neurochem Res. 2002 Oct; 27(10):1193-200.
      View in: PubMed
    71. O'brien DP, Luchette FA, Pereira SJ, Lim E, Seeskin CS, James L, Miller S, Davis K, Hurst JM, Johannigman JA, Frame SB. Pelvic fracture in the elderly is associated with increased mortality. Surgery. 2002 Oct; 132(4):710-4; discussion 714-5.
      View in: PubMed
    72. Tamminga CA, Nemeroff CB, Blakely RD, Brady L, Carter CS, Davis KL, Dingledine R, Gorman JM, Grigoriadis DE, Henderson DC, B Innis RB, Killen J, Laughren TP, McDonald WM, M Murphy GM, Paul SM, Rudorfer MV, Sausville E, Schatzberg AF, Scolnick EM, Suppes T. Developing novel treatments for mood disorders: accelerating discovery. Biol Psychiatry. 2002 Sep 15; 52(6):589-609.
      View in: PubMed
    73. Friedman JI, Harvey PD, McGurk SR, White L, Parrella M, Raykov T, Coleman T, Adler DN, Davis KL. Correlates of change in functional status of institutionalized geriatric schizophrenic patients: focus on medical comorbidity. Am J Psychiatry. 2002 Aug; 159(8):1388-94.
      View in: PubMed
    74. Haroutunian V, Davis KL. Issues and perspectives on brain tissue banking. Curr Psychiatry Rep. 2002 Aug; 4(4):233-4.
      View in: PubMed
    75. Gluck MR, Thomas RG, Davis KL, Haroutunian V. Implications for altered glutamate and GABA metabolism in the dorsolateral prefrontal cortex of aged schizophrenic patients. Am J Psychiatry. 2002 Jul; 159(7):1165-73.
      View in: PubMed
    76. Buchsbaum MS, Shihabuddin L, Hazlett EA, Schröder J, Haznedar MM, Powchik P, Spiegel-Cohen J, Wei T, Singer MB, Davis KL. Kraepelinian and non-Kraepelinian schizophrenia subgroup differences in cerebral metabolic rate. Schizophr Res. 2002 May 1; 55(1-2):25-40.
      View in: PubMed
    77. Friedman JI, Adler DN, Howanitz E, Harvey PD, Brenner G, Temporini H, White L, Parrella M, Davis KL. A double blind placebo controlled trial of donepezil adjunctive treatment to risperidone for the cognitive impairment of schizophrenia. Biol Psychiatry. 2002 Mar 1; 51(5):349-57.
      View in: PubMed
    78. Harvey PD, Moriarty PJ, Bowie C, Friedman JI, Parrella M, White L, Davis KL. Cortical and subcortical cognitive deficits in schizophrenia: convergence of classifications based on language and memory skill areas. J Clin Exp Neuropsychol. 2002 Feb; 24(1):55-66.
      View in: PubMed
    79. Davis KL. NSAID and Alzheimer's disease; possible answers and new questions. Mol Psychiatry. 2002; 7(9):925-6.
      View in: PubMed
    80. Parvathy S, Davies P, Haroutunian V, Purohit DP, Davis KL, Mohs RC, Park H, Moran TM, Chan JY, Buxbaum JD. Correlation between Abetax-40-, Abetax-42-, and Abetax-43-containing amyloid plaques and cognitive decline. Arch Neurol. 2001 Dec; 58(12):2025-32.
      View in: PubMed
    81. Smith RE, Haroutunian V, Davis KL, Meador-Woodruff JH. Vesicular glutamate transporter transcript expression in the thalamus in schizophrenia. Neuroreport. 2001 Sep 17; 12(13):2885-7.
      View in: PubMed
    82. Smith RE, Haroutunian V, Davis KL, Meador-Woodruff JH. Expression of excitatory amino acid transporter transcripts in the thalamus of subjects with schizophrenia. Am J Psychiatry. 2001 Sep; 158(9):1393-9.
      View in: PubMed
    83. Friedman JI, Adler DN, Temporini HD, Kemether E, Harvey PD, White L, Parrella M, Davis KL. Guanfacine treatment of cognitive impairment in schizophrenia. Neuropsychopharmacology. 2001 Sep; 25(3):402-9.
      View in: PubMed
    84. Friedman JI, Harvey PD, Coleman T, Moriarty PJ, Bowie C, Parrella M, White L, Adler D, Davis KL. Six-year follow-up study of cognitive and functional status across the lifespan in schizophrenia: a comparison with Alzheimer's disease and normal aging. Am J Psychiatry. 2001 Sep; 158(9):1441-8.
      View in: PubMed
    85. Dracheva S, Marras SA, Elhakem SL, Kramer FR, Davis KL, Haroutunian V. N-methyl-D-aspartic acid receptor expression in the dorsolateral prefrontal cortex of elderly patients with schizophrenia. Am J Psychiatry. 2001 Sep; 158(9):1400-10.
      View in: PubMed
    86. Harvey PD, Serper MR, White L, Parrella MJ, McGurk SR, Moriarty PJ, Bowie C, Vadhan N, Friedman J, Davis KL. The convergence of neuropsychological testing and clinical ratings of cognitive impairment in patients with schizophrenia. Compr Psychiatry. 2001 Jul-Aug; 42(4):306-13.
      View in: PubMed
    87. Buxbaum JD, Silverman JM, Smith CJ, Kilifarski M, Reichert J, Hollander E, Lawlor BA, Fitzgerald M, Greenberg DA, Davis KL. Evidence for a susceptibility gene for autism on chromosome 2 and for genetic heterogeneity. Am J Hum Genet. 2001 Jun; 68(6):1514-20.
      View in: PubMed
    88. Meador-Woodruff JH, Davis KL, Haroutunian V. Abnormal kainate receptor expression in prefrontal cortex in schizophrenia. Neuropsychopharmacology. 2001 May; 24(5):545-52.
      View in: PubMed
    89. Hakak Y, Walker JR, Li C, Wong WH, Davis KL, Buxbaum JD, Haroutunian V, Fienberg AA. Genome-wide expression analysis reveals dysregulation of myelination-related genes in chronic schizophrenia. Proc Natl Acad Sci U S A. 2001 Apr 10; 98(8):4746-51.
      View in: PubMed
    90. Schröder J, Buchsbaum MS, Shihabuddin L, Tang C, Wei TC, Spiegel-Cohen J, Hazlett EA, Abel L, Luu-Hsia C, Ciaravolo TM, Marin D, Davis KL. Patterns of cortical activity and memory performance in Alzheimer's disease. Biol Psychiatry. 2001 Mar 1; 49(5):426-36.
      View in: PubMed
    91. Jenkins LW, DeWitt DS, Johnston WE, Davis KL, Prough DS. Intraischemic mild hypothermia increases hippocampal CA1 blood flow during forebrain ischemia. Brain Res. 2001 Jan 26; 890(1):1-10.
      View in: PubMed
    92. Bowie CR, Moriarty PJ, Harvey PD, Parrella M, White L, Davis KL. Aggression in elderly schizophrenia patients: a comparison of nursing home and state hospital residents. J Neuropsychiatry Clin Neurosci. 2001; 13(3):357-66.
      View in: PubMed
    93. Moriarty PJ, Lieber D, Bennett A, White L, Parrella M, Harvey PD, Davis KL. Gender differences in poor outcome patients with lifelong schizophrenia. Schizophr Bull. 2001; 27(1):103-13.
      View in: PubMed
    94. Schneider LS, Tariot PN, Lyketsos CG, Dagerman KS, Davis KL, Davis S, Hsiao JK, Jeste DV, Katz IR, Olin JT, Pollock BG, Rabins PV, Rosenheck RA, Small GW, Lebowitz B, Lieberman JA. National Institute of Mental Health Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE): Alzheimer disease trial methodology. Am J Geriatr Psychiatry. 2001; 9(4):346-60.
      View in: PubMed
    95. Ibrahim HM, Hogg AJ, Healy DJ, Haroutunian V, Davis KL, Meador-Woodruff JH. Ionotropic glutamate receptor binding and subunit mRNA expression in thalamic nuclei in schizophrenia. Am J Psychiatry. 2000 Nov; 157(11):1811-23.
      View in: PubMed
    96. Haroutunian V, Serby M, Purohit DP, Perl DP, Marin D, Lantz M, Mohs RC, Davis KL. Contribution of Lewy body inclusions to dementia in patients with and without Alzheimer disease neuropathological conditions. Arch Neurol. 2000 Aug; 57(8):1145-50.
      View in: PubMed
    97. Sokolov BP, Tcherepanov AA, Haroutunian V, Davis KL. Levels of mRNAs encoding synaptic vesicle and synaptic plasma membrane proteins in the temporal cortex of elderly schizophrenic patients. Biol Psychiatry. 2000 Aug 1; 48(3):184-96.
      View in: PubMed
    98. Davis KL, Laine GA, Geissler HJ, Mehlhorn U, Brennan M, Allen SJ. Effects of myocardial edema on the development of myocardial interstitial fibrosis. Microcirculation. 2000 Aug; 7(4):269-80.
      View in: PubMed
    99. Marin DB, Dugue M, Schmeidler J, Santoro J, Neugroschl J, Zaklad G, Brickman A, Schnur E, Hoblyn J, Davis KL. The Caregiver Activity Survey (CAS): longitudinal validation of an instrument that measures time spent caregiving for individuals with Alzheimer's disease. Int J Geriatr Psychiatry. 2000 Aug; 15(8):680-6.
      View in: PubMed
    100. Silverman JM, Smith CM, Marin DB, Schmeidler J, Birstein S, Lantz M, Davis KL, Mohs RC. Has familial aggregation in Alzheimer's disease been overestimated? Int J Geriatr Psychiatry. 2000 Jul; 15(7):631-7.
      View in: PubMed
    101. Schachter AS, Davis KL. Alzheimer's disease. Dialogues Clin Neurosci. 2000 Jun; 2(2):91-100.
      View in: PubMed
    102. Harvey PD, Moriarty PJ, Friedman JI, White L, Parrella M, Mohs RC, Davis KL. Differential preservation of cognitive functions in geriatric patients with lifelong chronic schizophrenia: less impairment in reading compared with other skill areas. Biol Psychiatry. 2000 Jun 1; 47(11):962-8.
      View in: PubMed
    103. Harvey PD, Jacobsen H, Mancini D, Parrella M, White L, Haroutunian V, Davis KL. Clinical, cognitive and functional characteristics of long-stay patients with schizophrenia: a comparison of VA and state hospital patients. Schizophr Res. 2000 May 25; 43(1):3-9.
      View in: PubMed
    104. McGurk SR, Moriarty PJ, Harvey PD, Parrella M, White L, Davis KL. The longitudinal relationship of clinical symptoms, cognitive functioning, and adaptive life in geriatric schizophrenia. Schizophr Res. 2000 Mar 16; 42(1):47-55.
      View in: PubMed
    105. Näslund J, Haroutunian V, Mohs R, Davis KL, Davies P, Greengard P, Buxbaum JD. Correlation between elevated levels of amyloid beta-peptide in the brain and cognitive decline. JAMA. 2000 Mar 22-29; 283(12):1571-7.
      View in: PubMed
    106. Aisen PS, Davis KL, Berg JD, Schafer K, Campbell K, Thomas RG, Weiner MF, Farlow MR, Sano M, Grundman M, Thal LJ. A randomized controlled trial of prednisone in Alzheimer's disease. Alzheimer's Disease Cooperative Study. Neurology. 2000 Feb 8; 54(3):588-93.
      View in: PubMed
    107. Richardson-Burns SM, Haroutunian V, Davis KL, Watson SJ, Meador-Woodruff JH. Metabotropic glutamate receptor mRNA expression in the schizophrenic thalamus. Biol Psychiatry. 2000 Jan 1; 47(1):22-8.
      View in: PubMed
    108. McGurk SR, Moriarty PJ, Harvey PD, Parrella M, White L, Friedman J, Davis KL. Relationship of cognitive functioning, adaptive life skills, and negative symptom severity in poor-outcome geriatric schizophrenia patients. J Neuropsychiatry Clin Neurosci. 2000; 12(2):257-64.
      View in: PubMed
    109. Byne W, Stamu C, White L, Parrella M, Harvey PD, Davis KL. Prevalence and correlates of parkinsonism in an institutionalized population of geriatric patients with chronic schizophrenia. Int J Geriatr Psychiatry. 2000 Jan; 15(1):7-13.
      View in: PubMed
    110. Friedman JI, Adler DN, Davis KL. The role of norepinephrine in the pathophysiology of cognitive disorders: potential applications to the treatment of cognitive dysfunction in schizophrenia and Alzheimer's disease. Biol Psychiatry. 1999 Nov 1; 46(9):1243-52.
      View in: PubMed
    111. Davis KL, Mohs RC, Marin DB, Purohit DP, Perl DP, Lantz M, Austin G, Haroutunian V. Neuropeptide abnormalities in patients with early Alzheimer disease. Arch Gen Psychiatry. 1999 Nov; 56(11):981-7.
      View in: PubMed
    112. Friedman JI, Harvey PD, Kemether E, Byne W, Davis KL. Cognitive and functional changes with aging in schizophrenia. Biol Psychiatry. 1999 Oct 1; 46(7):921-8.
      View in: PubMed
    113. Davis KL, Braff DL, Weinberger DR. Protecting research subjects and psychiatric research: we can do both. Biol Psychiatry. 1999 Sep 15; 46(6):727-8.
      View in: PubMed
    114. Ehrenkrantz D, Silverman JM, Smith CJ, Birstein S, Marin D, Mohs RC, Davis KL. Genetic epidemiological study of maternal and paternal transmission of Alzheimer's disease. Am J Med Genet. 1999 Aug 20; 88(4):378-82.
      View in: PubMed
    115. Charney DS, Innis RB, Nestler EJ, Davis KL, Nemeroff CB, Weinberger DR. Increasing public trust and confidence in psychiatric research. Biol Psychiatry. 1999 Jul 1; 46(1):1-2.
      View in: PubMed
    116. Haroutunian V, Purohit DP, Perl DP, Marin D, Khan K, Lantz M, Davis KL, Mohs RC. Neurofibrillary tangles in nondemented elderly subjects and mild Alzheimer disease. Arch Neurol. 1999 Jun; 56(6):713-8.
      View in: PubMed
    117. Coutts M, Cui K, Davis KL, Keutzer JC, Sytkowski AJ. Regulated expression and functional role of the transcription factor CHOP (GADD153) in erythroid growth and differentiation. Blood. 1999 May 15; 93(10):3369-78.
      View in: PubMed
    118. Amin F, Silverman JM, Siever LJ, Smith CJ, Knott PJ, Davis KL. Genetic antecedents of dopamine dysfunction in schizophrenia. Biol Psychiatry. 1999 May 1; 45(9):1143-50.
      View in: PubMed
    119. Davis KL, Mohs RC, Marin D, Purohit DP, Perl DP, Lantz M, Austin G, Haroutunian V. Cholinergic markers in elderly patients with early signs of Alzheimer disease. JAMA. 1999 Apr 21; 281(15):1401-6.
      View in: PubMed
    120. Green CR, Marin DB, Mohs RC, Schmeidler J, Aryan M, Fine E, Davis KL. The impact of behavioral impairment of functional ability in Alzheimer's disease. Int J Geriatr Psychiatry. 1999 Apr; 14(4):307-16.
      View in: PubMed
    121. Byne W, Davis KL. The role of prefrontal cortex in the dopaminergic dysregulation of schizophrenia. Biol Psychiatry. 1999 Mar 15; 45(6):657-9.
      View in: PubMed
    122. Silverman JM, Smith CJ, Marin DB, Birstein S, Mare M, Mohs RC, Davis KL. Identifying families with likely genetic protective factors against Alzheimer disease. Am J Hum Genet. 1999 Mar; 64(3):832-8.
      View in: PubMed
    123. Anger WK, Storzbach D, Binder LM, Campbell KA, Rohlman DS, McCauley L, Kovera CA, Davis KL. Neurobehavioral deficits in Persian Gulf veterans: evidence from a population-based study. Portland Environmental Hazards Research Center. J Int Neuropsychol Soc. 1999 Mar; 5(3):203-12.
      View in: PubMed
    124. Campbell KA, Rohlman DS, Storzbach D, Binder LM, Anger WK, Kovera CA, Davis KL, Grossmann SJ. Test-retest reliability of psychological and neurobehavioral tests self-administered by computer. Assessment. 1999 Mar; 6(1):21-32.
      View in: PubMed
    125. Davis KL. Alzheimer's disease: seeking new ways to preserve brain function. Interview by Alice V. Luddington. Geriatrics. 1999 Feb; 54(2):42-7; quiz 48.
      View in: PubMed
    126. Samuels SC, Silverman JM, Marin DB, Peskind ER, Younki SG, Greenberg DA, Schnur E, Santoro J, Davis KL. CSF beta-amyloid, cognition, and APOE genotype in Alzheimer's disease. Neurology. 1999 Feb; 52(3):547-51.
      View in: PubMed
    127. Harvey PD, Parrella M, White L, Mohs RC, Davidson M, Davis KL. Convergence of cognitive and adaptive decline in late-life schizophrenia. Schizophr Res. 1999 Jan 4; 35(1):77-84.
      View in: PubMed
    128. Harvey PD, Silverman JM, Mohs RC, Parrella M, White L, Powchik P, Davidson M, Davis KL. Cognitive decline in late-life schizophrenia: a longitudinal study of geriatric chronically hospitalized patients. Biol Psychiatry. 1999 Jan 1; 45(1):32-40.
      View in: PubMed
    129. Friedman JI, Temporini H, Davis KL. Pharmacologic strategies for augmenting cognitive performance in schizophrenia. Biol Psychiatry. 1999 Jan 1; 45(1):1-16.
      View in: PubMed
    130. Healy DJ, Haroutunian V, Powchik P, Davidson M, Davis KL, Watson SJ, Meador-Woodruff JH. AMPA receptor binding and subunit mRNA expression in prefrontal cortex and striatum of elderly schizophrenics. Neuropsychopharmacology. 1998 Oct; 19(4):278-86.
      View in: PubMed
    131. Marin DB, Breuer B, Marin ML, Silverman J, Schmeidler J, Greenberg D, Flynn S, Mare M, Lantz M, Libow L, Neufeld R, Altstiel L, Davis KL, Mohs RC. The relationship between apolipoprotein E, dementia, and vascular illness. Atherosclerosis. 1998 Sep; 140(1):173-80.
      View in: PubMed
    132. Haroutunian V, Perl DP, Purohit DP, Marin D, Khan K, Lantz M, Davis KL, Mohs RC. Regional distribution of neuritic plaques in the nondemented elderly and subjects with very mild Alzheimer disease. Arch Neurol. 1998 Sep; 55(9):1185-91.
      View in: PubMed
    133. Davis KL, Jenkins LW, DeWitt DS, Prough DS. Mild traumatic brain injury does not modify the cerebral blood flow profile of secondary forebrain ischemia in Wistar rats. J Neurotrauma. 1998 Aug; 15(8):615-25.
      View in: PubMed
    134. Harvey PD, Howanitz E, Parrella M, White L, Davidson M, Mohs RC, Hoblyn J, Davis KL. Symptoms, cognitive functioning, and adaptive skills in geriatric patients with lifelong schizophrenia: a comparison across treatment sites. Am J Psychiatry. 1998 Aug; 155(8):1080-6.
      View in: PubMed
    135. Byne W, White L, Parella M, Adams R, Harvey PD, Davis KL. Tardive dyskinesia in a chronically institutionalized population of elderly schizophrenic patients: prevalence and association with cognitive impairment. Int J Geriatr Psychiatry. 1998 Jul; 13(7):473-9.
      View in: PubMed
    136. Davis KL, Buchsbaum MS, Shihabuddin L, Spiegel-Cohen J, Metzger M, Frecska E, Keefe RS, Powchik P. Ventricular enlargement in poor-outcome schizophrenia. Biol Psychiatry. 1998 Jun 1; 43(11):783-93.
      View in: PubMed
    137. Mehlhorn U, Allen SJ, Davis KL, Geissler HJ, Warters RD, Rainer de Vivie E. Increasing the colloid osmotic pressure of cardiopulmonary bypass prime and normothermic blood cardioplegia minimizes myocardial oedema and prevents cardiac dysfunction. Cardiovasc Surg. 1998 Jun; 6(3):274-81.
      View in: PubMed
    138. Samuels SC, Davis KL. Experimental approaches to cognitive disturbance in Alzheimer's disease. Harv Rev Psychiatry. 1998 May-Jun; 6(1):11-22.
      View in: PubMed
    139. Gabriel SM, Marin DB, Aisen PS, Lantz M, Altstiel LD, Davis KL, Mohs RC. Association of elevated alpha 1-antichymotrypsin with cognitive impairment in a prospective study of the very old. Am J Psychiatry. 1998 May; 155(5):698-700.
      View in: PubMed
    140. Purohit DP, Perl DP, Haroutunian V, Powchik P, Davidson M, Davis KL. Alzheimer disease and related neurodegenerative diseases in elderly patients with schizophrenia: a postmortem neuropathologic study of 100 cases. Arch Gen Psychiatry. 1998 Mar; 55(3):205-11.
      View in: PubMed
    141. Sytkowski AJ, Lunn ED, Davis KL, Feldman L, Siekman S. Human erythropoietin dimers with markedly enhanced in vivo activity. Proc Natl Acad Sci U S A. 1998 Feb 3; 95(3):1184-8.
      View in: PubMed
    142. Silverman JM, Smith CJ, Guo SL, Mohs RC, Siever LJ, Davis KL. Lateral ventricular enlargement in schizophrenic probands and their siblings with schizophrenia-related disorders. Biol Psychiatry. 1998 Jan 15; 43(2):97-106.
      View in: PubMed
    143. Powchik P, Davidson M, Haroutunian V, Gabriel SM, Purohit DP, Perl DP, Harvey PD, Davis KL. Postmortem studies in schizophrenia. Schizophr Bull. 1998; 24(3):325-41.
      View in: PubMed
    144. Davis KL. Future therapeutic approaches to Alzheimer's disease. J Clin Psychiatry. 1998; 59 Suppl 11:14-6.
      View in: PubMed
    145. Meador-Woodruff JH, Haroutunian V, Powchik P, Davidson M, Davis KL, Watson SJ. Dopamine receptor transcript expression in striatum and prefrontal and occipital cortex. Focal abnormalities in orbitofrontal cortex in schizophrenia. Arch Gen Psychiatry. 1997 Dec; 54(12):1089-95.
      View in: PubMed
    146. Marin DB, Green CR, Schmeidler J, Harvey PD, Lawlor BA, Ryan TM, Aryan M, Davis KL, Mohs RC. Noncognitive disturbances in Alzheimer's disease: frequency, longitudinal course, and relationship to cognitive symptoms. J Am Geriatr Soc. 1997 Nov; 45(11):1331-8.
      View in: PubMed
    147. Davis KL, Marin DB, Kane R, Patrick D, Peskind ER, Raskind MA, Puder KL. The Caregiver Activity Survey (CAS): development and validation of a new measure for caregivers of persons with Alzheimer's disease. Int J Geriatr Psychiatry. 1997 Oct; 12(10):978-88.
      View in: PubMed
    148. Gabriel SM, Haroutunian V, Powchik P, Honer WG, Davidson M, Davies P, Davis KL. Increased concentrations of presynaptic proteins in the cingulate cortex of subjects with schizophrenia. Arch Gen Psychiatry. 1997 Jun; 54(6):559-66.
      View in: PubMed
    149. Haroutunian V, Greig N, Pei XF, Utsuki T, Gluck R, Acevedo LD, Davis KL, Wallace WC. Pharmacological modulation of Alzheimer's beta-amyloid precursor protein levels in the CSF of rats with forebrain cholinergic system lesions. Brain Res Mol Brain Res. 1997 Jun; 46(1-2):161-8.
      View in: PubMed
    150. Aisen PS, Davis KL. The search for disease-modifying treatment for Alzheimer's disease. Neurology. 1997 May; 48(5 Suppl 6):S35-41.
      View in: PubMed
    151. Li G, Aryan M, Silverman JM, Haroutunian V, Perl DP, Birstein S, Lantz M, Marin DB, Mohs RC, Davis KL. The validity of the family history method for identifying Alzheimer disease. Arch Neurol. 1997 May; 54(5):634-40.
      View in: PubMed
    152. Li G, Silverman JM, Smith CJ, Zaccario ML, Wentzel-Bell C, Siever LJ, Mohs RC, Davis KL. Validity of the family history method for identifying schizophrenia-related disorders. Psychiatry Res. 1997 Apr 18; 70(1):39-48.
      View in: PubMed
    153. Harvey PD, Lombardi J, Leibman M, Parrella M, White L, Powchik P, Mohs RC, Davidson M, Davis KL. Age-related differences in formal thought disorder in chronically hospitalized schizophrenic patients: a cross-sectional study across nine decades. Am J Psychiatry. 1997 Feb; 154(2):205-10.
      View in: PubMed
    154. Keefe RS, Silverman JM, Mohs RC, Siever LJ, Harvey PD, Friedman L, Roitman SE, DuPre RL, Smith CJ, Schmeidler J, Davis KL. Eye tracking, attention, and schizotypal symptoms in nonpsychotic relatives of patients with schizophrenia. Arch Gen Psychiatry. 1997 Feb; 54(2):169-76.
      View in: PubMed
    155. Samuels SC, Davis KL. A risk-benefit assessment of tacrine in the treatment of Alzheimer's disease. Drug Saf. 1997 Jan; 16(1):66-77.
      View in: PubMed
    156. Li Y, Davis KL, Sytkowski AJ. Protein kinase C-epsilon is necessary for erythropoietin's up-regulation of c-myc and for factor-dependent DNA synthesis. Evidence for discrete signals for growth and differentiation. J Biol Chem. 1996 Oct 25; 271(43):27025-30.
      View in: PubMed
    157. Harvey PD, Davidson M, White L, Keefe RS, Hirschowitz J, Mohs RC, Davis KL. Empirical evaluation of the factorial structure of clinical symptoms in schizophrenia: effects of typical neuroleptics on the brief psychiatric rating scale. Biol Psychiatry. 1996 Oct 15; 40(8):755-60.
      View in: PubMed
    158. Grodberg J, Davis KL, Sytkowski AJ. Functional and structural role of arginine 103 in human erythropoietin. Arch Biochem Biophys. 1996 Sep 15; 333(2):427-31.
      View in: PubMed
    159. Kovera CA, Anger WK, Campbell KA, Binder LM, Storzbach D, Davis KL, Rohlman DS. Computer-administration of questionnaires: a health screening system (HSS) developed for veterans. Neurotoxicol Teratol. 1996 Jul-Aug; 18(4):511-8.
      View in: PubMed
    160. Aisen PS, Marin D, Altstiel L, Goodwin C, Baruch B, Jacobson R, Ryan T, Davis KL. A pilot study of prednisone in Alzheimer's disease. Dementia. 1996 Jul-Aug; 7(4):201-6.
      View in: PubMed
    161. Shihabuddin L, Silverman JM, Buchsbaum MS, Seiver LJ, Luu C, Germans MK, Metzger M, Mohs RC, Smith CJ, Spiegel-Cohen J, Davis KL. Ventricular enlargement associated with linkage marker for schizophrenia-related disorders in one pedigree. Mol Psychiatry. 1996 Jul; 1(3):215-22.
      View in: PubMed
    162. Meador-Woodruff JH, Damask SP, Wang J, Haroutunian V, Davis KL, Watson SJ. Dopamine receptor mRNA expression in human striatum and neocortex. Neuropsychopharmacology. 1996 Jul; 15(1):17-29.
      View in: PubMed
    163. Keefe RS, Frescka E, Apter SH, Davidson M, Macaluso JM, Hirschowitz J, Davis KL. Clinical characteristics of Kraepelinian schizophrenia: replication and extension of previous findings. Am J Psychiatry. 1996 Jun; 153(6):806-11.
      View in: PubMed
    164. Silverman JM, Greenberg DA, Altstiel LD, Siever LJ, Mohs RC, Smith CJ, Zhou G, Hollander TE, Yang XP, Kedache M, Li G, Zaccario ML, Davis KL. Evidence of a locus for schizophrenia and related disorders on the short arm of chromosome 5 in a large pedigree. Am J Med Genet. 1996 Apr 9; 67(2):162-71.
      View in: PubMed
    165. Serby M, Mohan C, Aryan M, Williams L, Mohs RC, Davis KL. Olfactory identification deficits in relatives of Alzheimer's disease patients. Biol Psychiatry. 1996 Mar 1; 39(5):375-7.
      View in: PubMed
    166. Davis KL. Progress in understanding the pathogenesis of Alzheimer's disease. Mol Psychiatry. 1996 Mar; 1(1):11-2.
      View in: PubMed
    167. Gabriel SM, Davidson M, Haroutunian V, Powchik P, Bierer LM, Purohit DP, Perl DP, Davis KL. Neuropeptide deficits in schizophrenia vs. Alzheimer's disease cerebral cortex. Biol Psychiatry. 1996 Jan 15; 39(2):82-91.
      View in: PubMed
    168. Li G, Silverman JM, Altstiel LD, Haroutunian V, Perl DP, Purohit D, Birstein S, Lantz M, Mohs RC, Davis KL. Apolipoprotein E-epsilon 4 allele and familial risk in Alzheimer's disease. Genet Epidemiol. 1996; 13(3):285-98.
      View in: PubMed
    169. Davis KL. Issues in accelerating the pace of development for neuroprotective agents. Alzheimer Dis Assoc Disord. 1996; 10 Suppl 1:36-7.
      View in: PubMed
    170. Marin DB, Bierer LM, Lawlor BA, Ryan TM, Jacobson R, Schmeidler J, Mohs RC, Davis KL. L-deprenyl and physostigmine for the treatment of Alzheimer's disease. Psychiatry Res. 1995 Oct 16; 58(3):181-9.
      View in: PubMed
    171. Salom IL, Davis K. Prescribing for older patients: how to avoid toxic drug reactions. Geriatrics. 1995 Oct; 50(10):37-40, 43; discussion 44-5.
      View in: PubMed
    172. Keefe RS, Roitman SE, Harvey PD, Blum CS, DuPre RL, Prieto DM, Davidson M, Davis KL. A pen-and-paper human analogue of a monkey prefrontal cortex activation task: spatial working memory in patients with schizophrenia. Schizophr Res. 1995 Sep; 17(1):25-33.
      View in: PubMed
    173. Lawlor BA, Bierer LM, Ryan TM, Schmeidler J, Knott PJ, Williams LL, Mohs RC, Davis KL. Plasma 3-methoxy-4-hydroxyphenylglycol (MHPG) and clinical symptoms in Alzheimer's disease. Biol Psychiatry. 1995 Aug 1; 38(3):185-8.
      View in: PubMed
    174. Wallace WC, Lieberburg I, Schenk D, Vigo-Pelfrey C, Davis KL, Haroutunian V. Chronic elevation of secreted amyloid precursor protein in subcortically lesioned rats, and its exacerbation in aged rats. J Neurosci. 1995 Jul; 15(7 Pt 1):4896-905.
      View in: PubMed
    175. Lawlor BA, Ryan TM, Bierer LM, Schmeidler J, Haroutunian V, Mohs R, Davis KL. Lack of association between clinical symptoms and postmortem indices of brain serotonin function in Alzheimer's disease. Biol Psychiatry. 1995 Jun 15; 37(12):895-6.
      View in: PubMed
    176. Davis KL, Powchik P. Tacrine. Lancet. 1995 Mar 11; 345(8950):625-30.
      View in: PubMed
    177. Li G, Silverman JM, Smith CJ, Zaccario ML, Schmeidler J, Mohs RC, Davis KL. Age at onset and familial risk in Alzheimer's disease. Am J Psychiatry. 1995 Mar; 152(3):424-30.
      View in: PubMed
    178. Bierer LM, Haroutunian V, Gabriel S, Knott PJ, Carlin LS, Purohit DP, Perl DP, Schmeidler J, Kanof P, Davis KL. Neurochemical correlates of dementia severity in Alzheimer's disease: relative importance of the cholinergic deficits. J Neurochem. 1995 Feb; 64(2):749-60.
      View in: PubMed
    179. Altstiel LD, Lawlor B, Mohs R, Schmeidler J, Dalton A, Mehta P, Davis K. Elevated alpha 1-antichymotrypsin serum levels in a subset of nondemented first-degree relatives of Alzheimer's disease patients. Dementia. 1995 Jan-Feb; 6(1):17-20.
      View in: PubMed
    180. Bierer LM, Hof PR, Purohit DP, Carlin L, Schmeidler J, Davis KL, Perl DP. Neocortical neurofibrillary tangles correlate with dementia severity in Alzheimer's disease. Arch Neurol. 1995 Jan; 52(1):81-8.
      View in: PubMed
    181. Stern RG, Kahn RS, Davidson M, Nora RM, Davis KL. Early response to clozapine in schizophrenia. Am J Psychiatry. 1994 Dec; 151(12):1817-8.
      View in: PubMed
    182. Lawlor BA, Ryan TM, Schmeidler J, Mohs RC, Davis KL. Clinical symptoms associated with age at onset in Alzheimer's disease. Am J Psychiatry. 1994 Nov; 151(11):1646-9.
      View in: PubMed
    183. Bierer LM, Aisen PS, Davidson M, Ryan TM, Schmeidler J, Davis KL. A pilot study of clonidine plus physostigmine in Alzheimer's disease. Dementia. 1994 Sep-Oct; 5(5):243-6.
      View in: PubMed
    184. Aisen PS, Davis KL. Inflammatory mechanisms in Alzheimer's disease: implications for therapy. Am J Psychiatry. 1994 Aug; 151(8):1105-13.
      View in: PubMed
    185. Keefe RS, Silverman JM, Roitman SE, Harvey PD, Duncan MA, Alroy D, Siever LJ, Davis KL, Mohs RC. Performance of nonpsychotic relatives of schizophrenic patients on cognitive tests. Psychiatry Res. 1994 Jul; 53(1):1-12.
      View in: PubMed
    186. Silverman JM, Li G, Zaccario ML, Smith CJ, Schmeidler J, Mohs RC, Davis KL. Patterns of risk in first-degree relatives of patients with Alzheimer's disease. Arch Gen Psychiatry. 1994 Jul; 51(7):577-86.
      View in: PubMed
    187. Kahn RS, Davidson M, Siever LJ, Sevy S, Davis KL. Clozapine treatment and its effect on neuroendocrine responses induced by the serotonin agonist, m-chlorophenylpiperazine. Biol Psychiatry. 1994 Jun 15; 35(12):909-12.
      View in: PubMed
    188. Haroutunian V, Davidson M, Kanof PD, Perl DP, Powchik P, Losonczy M, McCrystal J, Purohit DP, Bierer LM, Davis KL. Cortical cholinergic markers in schizophrenia. Schizophr Res. 1994 May; 12(2):137-44.
      View in: PubMed
    189. Perry EK, Haroutunian V, Davis KL, Levy R, Lantos P, Eagger S, Honavar M, Dean A, Griffiths M, McKeith IG, et al. Neocortical cholinergic activities differentiate Lewy body dementia from classical Alzheimer's disease. Neuroreport. 1994 Mar 21; 5(7):747-9.
      View in: PubMed
    190. Stern RG, Mohs RC, Davidson M, Schmeidler J, Silverman J, Kramer-Ginsberg E, Searcey T, Bierer L, Davis KL. A longitudinal study of Alzheimer's disease: measurement, rate, and predictors of cognitive deterioration. Am J Psychiatry. 1994 Mar; 151(3):390-6.
      View in: PubMed
    191. Miller AH, Sastry G, Speranza AJ, Lawlor BA, Mohs RC, Ryan TM, Gabriel SM, Serby M, Schmeidler J, Davis KL. Lack of association between cortisol hypersecretion and nonsuppression on the DST in patients with Alzheimer's disease. Am J Psychiatry. 1994 Feb; 151(2):267-70.
      View in: PubMed
    192. Kahn RS, Harvey PD, Davidson M, Keefe RS, Apter S, Neale JM, Mohs RC, Davis KL. Neuropsychological correlates of central monoamine function in chronic schizophrenia: relationship between CSF metabolites and cognitive function. Schizophr Res. 1994 Feb; 11(3):217-24.
      View in: PubMed
    193. Davis KL. Acceleration of the development of a treatment for Alzheimer's disease. Neurobiol Aging. 1994; 15 Suppl 2:S55-6.
      View in: PubMed
    194. Bierer LM, Knott PJ, Schmeidler JM, Marin DB, Ryan TM, Haroutunian V, Purohit DP, Perl DP, Mohs RC, Davis KL. Post-mortem examination of dopaminergic parameters in Alzheimer's disease: relationship to noncognitive symptoms. Psychiatry Res. 1993 Dec; 49(3):211-7.
      View in: PubMed
    195. Schmauss C, Haroutunian V, Davis KL, Davidson M. Selective loss of dopamine D3-type receptor mRNA expression in parietal and motor cortices of patients with chronic schizophrenia. Proc Natl Acad Sci U S A. 1993 Oct 1; 90(19):8942-6.
      View in: PubMed
    196. Wallace W, Ahlers ST, Gotlib J, Bragin V, Sugar J, Gluck R, Shea PA, Davis KL, Haroutunian V. Amyloid precursor protein in the cerebral cortex is rapidly and persistently induced by loss of subcortical innervation. Proc Natl Acad Sci U S A. 1993 Sep 15; 90(18):8712-6.
      View in: PubMed
    197. Kahn RS, Davidson M, Siever L, Gabriel S, Apter S, Davis KL. Serotonin function and treatment response to clozapine in schizophrenic patients. Am J Psychiatry. 1993 Sep; 150(9):1337-42.
      View in: PubMed
    198. Kahn RS, Davidson M, Knott P, Stern RG, Apter S, Davis KL. Effect of neuroleptic medication on cerebrospinal fluid monoamine metabolite concentrations in schizophrenia. Serotonin-dopamine interactions as a target for treatment. Arch Gen Psychiatry. 1993 Aug; 50(8):599-605.
      View in: PubMed
    199. Green CR, Mohs RC, Schmeidler J, Aryan M, Davis KL. Functional decline in Alzheimer's disease: a longitudinal study. J Am Geriatr Soc. 1993 Jun; 41(6):654-61.
      View in: PubMed
    200. Gabriel SM, Bierer LM, Harotunian V, Purohit DP, Perl DP, Davis KL. Widespread deficits in somatostatin but not neuropeptide Y concentrations in Alzheimer's disease cerebral cortex. Neurosci Lett. 1993 May 28; 155(1):116-20.
      View in: PubMed
    201. Silverman JM, Siever LJ, Horvath TB, Coccaro EF, Klar H, Davidson M, Pinkham L, Apter SH, Mohs RC, Davis KL. Schizophrenia-related and affective personality disorder traits in relatives of probands with schizophrenia and personality disorders. Am J Psychiatry. 1993 Mar; 150(3):435-42.
      View in: PubMed
    202. Purohit DP, Davidson M, Perl DP, Powchik P, Haroutunian VH, Bierer LM, McCrystal J, Losonczy M, Davis KL. Severe cognitive impairment in elderly schizophrenic patients: a clinicopathological study. Biol Psychiatry. 1993 Feb 15; 33(4):255-60.
      View in: PubMed
    203. Davidson M, Kahn RS, Stern RG, Hirschowitz J, Apter S, Knott P, Davis KL. Treatment with clozapine and its effect on plasma homovanillic acid and norepinephrine concentrations in schizophrenia. Psychiatry Res. 1993 Feb; 46(2):151-63.
      View in: PubMed
    204. Bierer LM, Aisen PS, Davidson M, Ryan TM, Stern RG, Schmeidler J, Davis KL. A pilot study of oral physostigmine plus yohimbine in patients with Alzheimer disease. Alzheimer Dis Assoc Disord. 1993; 7(2):98-104.
      View in: PubMed
    205. Keefe RS, Harvey PD, Lenzenweger MF, Davidson M, Apter SH, Schmeidler J, Mohs RC, Davis KL. Empirical assessment of the factorial structure of clinical symptoms in schizophrenia: negative symptoms. Psychiatry Res. 1992 Nov; 44(2):153-65.
      View in: PubMed
    206. Davis KL, Thal LJ, Gamzu ER, Davis CS, Woolson RF, Gracon SI, Drachman DA, Schneider LS, Whitehouse PJ, Hoover TM, et al. A double-blind, placebo-controlled multicenter study of tacrine for Alzheimer's disease. The Tacrine Collaborative Study Group. N Engl J Med. 1992 Oct 29; 327(18):1253-9.
      View in: PubMed
    207. Tsuboyama GK, Gabriel SS, Davis BM, Davison M, Lawlor BA, Ware K, Davis KL, Mohs RC. Neuroendocrine dysfunction in Alzheimer's disease: results following TRH stimulation. Biol Psychiatry. 1992 Jul 15; 32(2):195-8.
      View in: PubMed
    208. Stern RG, Mohs RC, Bierer LM, Silverman JM, Schmeidler J, Davidson M, Davis KL. Deterioration on the Blessed test in Alzheimer's disease: longitudinal data and their implications for clinical trials and identification of subtypes. Psychiatry Res. 1992 May; 42(2):101-10.
      View in: PubMed
    209. Lawlor BA, Tsuboyama G, Ryan T, Mohs RC, Davis BM, Davidson M, Gabriel S, Davis KL. Agitation and postdexamethasone cortisol levels in Alzheimer's disease. Am J Psychiatry. 1992 Apr; 149(4):546-8.
      View in: PubMed
    210. Lawlor BA, Davis KL. Does modulation of glutamatergic function represent a viable therapeutic strategy in Alzheimer's disease? Biol Psychiatry. 1992 Feb 15; 31(4):337-50.
      View in: PubMed
    211. Kahn RS, Davidson M, Hirschowitz J, Stern RG, Davis BM, Gabriel S, Moore C, Davis KL. Nocturnal growth hormone secretion in schizophrenic patients and healthy subjects. Psychiatry Res. 1992 Feb; 41(2):155-61.
      View in: PubMed
    212. Amin F, Davidson M, Davis KL. Homovanillic acid measurement in clinical research: a review of methodology. Schizophr Bull. 1992; 18(1):123-48.
      View in: PubMed
    213. Davidson M, Kahn RS, Stern RG, Harvey PD, Keefe R, Knott P, Apter S, Webster L, Davis KL. Measurements of plasma homovanillic acid in schizophrenic patients. Clin Neuropharmacol. 1992; 15 Suppl 1 Pt A:521A-522A.
      View in: PubMed
    214. Feldman L, Heinzerling R, Hillam RP, Chern YE, Frazier JG, Davis KL, Sytkowski AJ. Four unique monoclonal antibodies to the putative receptor binding domain of erythropoietin inhibit the biological function of the hormone. Exp Hematol. 1992 Jan; 20(1):64-8.
      View in: PubMed
    215. Siever LJ, Davis KL. A psychobiological perspective on the personality disorders. Am J Psychiatry. 1991 Dec; 148(12):1647-58.
      View in: PubMed
    216. Davis KL, Kahn RS, Ko G, Davidson M. Dopamine in schizophrenia: a review and reconceptualization. Am J Psychiatry. 1991 Nov; 148(11):1474-86.
      View in: PubMed
    217. Davidson M, Kahn RS, Knott P, Kaminsky R, Cooper M, DuMont K, Apter S, Davis KL. Effects of neuroleptic treatment on symptoms of schizophrenia and plasma homovanillic acid concentrations. Arch Gen Psychiatry. 1991 Oct; 48(10):910-3.
      View in: PubMed
    218. Siever LJ, Amin F, Coccaro EF, Bernstein D, Kavoussi RJ, Kalus O, Horvath TB, Warne P, Davidson M, Davis KL. Plasma homovanillic acid in schizotypal personality disorder. Am J Psychiatry. 1991 Sep; 148(9):1246-8.
      View in: PubMed
    219. Harvey PD, Davidson M, Powchik P, Schmeidler J, McQueeney R, Kaminsky R, Davis KL. Time course and clinical predictors of treatment response in schizophrenia. Schizophr Res. 1991 Sep; 5(2):161-6.
      View in: PubMed
    220. Harvey PD, Putnam KM, Davidson M, Kahn RS, Powchik P, McQueeney R, Keefe RS, Davis KL. Brief neuroleptic discontinuation and clinical symptoms in Kraepelinian and non-Kraepelinian chronic schizophrenic patients. Psychiatry Res. 1991 Sep; 38(3):285-92.
      View in: PubMed
    221. Wallace WC, Bragin V, Robakis NK, Sambamurti K, VanderPutten D, Merril CR, Davis KL, Santucci AC, Haroutunian V. Increased biosynthesis of Alzheimer amyloid precursor protein in the cerebral cortex of rats with lesions of the nucleus basalis of Meynert. Brain Res Mol Brain Res. 1991 May; 10(2):173-8.
      View in: PubMed
    222. Keefe RS, Lobel DS, Mohs RC, Silverman JM, Harvey PD, Davidson M, Losonczy MF, Davis KL. Diagnostic issues in chronic schizophrenia: kraepelinian schizophrenia, undifferentiated schizophrenia, and state-independent negative symptoms. Schizophr Res. 1991 Mar-Apr; 4(2):71-9.
      View in: PubMed
    223. Kahn RS, Davidson M, Kanof P, McQueeney RT, Singh RR, Davis KL. Effects of indomethacin on plasma homovanillic acid concentration in normal subjects: a study of prostaglandin-dopamine interactions. Psychopharmacology (Berl). 1991; 103(1):95-8.
      View in: PubMed
    224. Santucci AC, Haroutunian V, Davis KL. Pharmacological alleviation of combined cholinergic/noradrenergic lesion-induced memory deficits in rats. Clin Neuropharmacol. 1991; 14 Suppl 1:S1-8.
      View in: PubMed
    225. Kanof PD, Mohs RC, Gross J, Davidson M, Bierer LM, Davis KL. Platelet phospholipid synthesis in Alzheimer's disease. Neurobiol Aging. 1991 Jan-Feb; 12(1):65-9.
      View in: PubMed
    226. Davidson M, Kahn RS, Powchik P, Warne P, Losonczy MF, Kaminsky R, Apter S, Jaff S, Davis KL. Changes in plasma homovanillic acid concentrations in schizophrenic patients following neuroleptic discontinuation. Arch Gen Psychiatry. 1991 Jan; 48(1):73-6.
      View in: PubMed
    227. Zemishlany Z, Patterson D, Davis KL, Hards RG. Glycinamide ribonucleotide synthetase activity in lymphocytes from patients with Alzheimer's disease and normal controls. Biol Psychiatry. 1990 Dec 15; 28(12):1058-60.
      View in: PubMed
    228. Harvey PD, Keefe RS, Moskowitz J, Putnam KM, Mohs RC, Davis KL. Attentional markers of vulnerability to schizophrenia: performance of medicated and unmedicated patients and normals. Psychiatry Res. 1990 Aug; 33(2):179-88.
      View in: PubMed
    229. Siever LJ, Silverman JM, Horvath TB, Klar H, Coccaro E, Keefe RS, Pinkham L, Rinaldi P, Mohs RC, Davis KL. Increased morbid risk for schizophrenia-related disorders in relatives of schizotypal personality disordered patients. Arch Gen Psychiatry. 1990 Jul; 47(7):634-40.
      View in: PubMed
    230. Davidson M, Harvey PD, Bergman RL, Powchik P, Kaminsky R, Losonczy MF, Davis KL. Effects of the D-1 agonist SKF-38393 combined with haloperidol in schizophrenic patients. Arch Gen Psychiatry. 1990 Feb; 47(2):190-1.
      View in: PubMed
    231. Haroutunian V, Kanof PD, Tsuboyama G, Davis KL. Restoration of cholinomimetic activity by clonidine in cholinergic plus noradrenergic lesioned rats. Brain Res. 1990 Jan 22; 507(2):261-6.
      View in: PubMed
    232. Bierer LM, Perl DP, Haroutunian V, Mohs RC, Davis KL. Neurofibrillary tangles, Alzheimer's disease and Lewy bodies. Lancet. 1990 Jan 20; 335(8682):163.
      View in: PubMed
    233. Haroutunian V, Santucci AC, Davis KL. Implications of multiple transmitter system lesions for cholinomimetic therapy in Alzheimer's disease. Prog Brain Res. 1990; 84:333-46.
      View in: PubMed
    234. Gamzu ER, Thal LJ, Davis KL. Therapeutic trials using tacrine and other cholinesterase inhibitors. Adv Neurol. 1990; 51:241-5.
      View in: PubMed
    235. Greenwald BS, Kramer-Ginsberg E, Marin DB, Laitman LB, Hermann CK, Mohs RC, Davis KL. Dementia with coexistent major depression. Am J Psychiatry. 1989 Nov; 146(11):1472-8.
      View in: PubMed
    236. Haroutunian V, Kanof PD, Davis KL. Interactions of forebrain cholinergic and somatostatinergic systems in the rat. Brain Res. 1989 Sep 4; 496(1-2):98-104.
      View in: PubMed
    237. Davis KL. Toward a therapeutic strategy based on amyloid precursor protein: unanswered questions. Neurobiol Aging. 1989 Sep-Oct; 10(5):475-6; discussion 477-8.
      View in: PubMed
    238. Shutske GM, Pierrat FA, Kapples KJ, Cornfeldt ML, Szewczak MR, Huger FP, Bores GM, Haroutunian V, Davis KL. 9-Amino-1,2,3,4-tetrahydroacridin-1-ols: synthesis and evaluation as potential Alzheimer's disease therapeutics. J Med Chem. 1989 Aug; 32(8):1805-13.
      View in: PubMed
    239. Coccaro EF, Siever LJ, Klar HM, Maurer G, Cochrane K, Cooper TB, Mohs RC, Davis KL. Serotonergic studies in patients with affective and personality disorders. Correlates with suicidal and impulsive aggressive behavior. Arch Gen Psychiatry. 1989 Jul; 46(7):587-99.
      View in: PubMed
    240. Haroutunian V, Kanof PD, Davis KL. Attenuation of nucleus basalis of Meynert lesion-induced cholinergic deficits by nerve growth factor. Brain Res. 1989 May 15; 487(1):200-3.
      View in: PubMed
    241. Kanof PD, Coccaro EF, Johns CA, Davidson M, Siever LJ, Davis KL. Cyclic-AMP production by polymorphonuclear leukocytes in psychiatric disorders. Biol Psychiatry. 1989 Feb 15; 25(4):413-20.
      View in: PubMed
    242. Keefe RS, Mohs RC, Losonczy MF, Davidson M, Silverman JM, Horvath TB, Davis KL. Premorbid sociosexual functioning and long-term outcome in schizophrenia. Am J Psychiatry. 1989 Feb; 146(2):206-11.
      View in: PubMed
    243. Keefe RS, Siever LJ, Mohs RC, Peterson AE, Mahon TR, Bergman RL, Davis KL. Eye tracking, schizophrenic symptoms, and schizotypal personality disorder. Eur Arch Psychiatry Neurol Sci. 1989; 239(1):39-42.
      View in: PubMed
    244. Harvey PD, Davidson M, Davis KL, Bastiaens L. Change in subtype presentation in schizophrenics. Compr Psychiatry. 1989 Jan-Feb; 30(1):114-6.
      View in: PubMed
    245. Davidson M, Bierer LM, Kaminsky R, Ryan TM, Davis KL. Combined administration of physostigmine and clonidine to patients with dementia of the Alzheimer type: a pilot safety study. Alzheimer Dis Assoc Disord. 1989; 3(4):224-7.
      View in: PubMed
    246. Santucci AC, Haroutunian V, Tsuboyama GK, Kanof PD, Davis KL. Therapeutics of Alzheimer's disease for clinical and pre-clinical issues. Prog Clin Biol Res. 1989; 317:1111-20.
      View in: PubMed
    247. Silverman JM, Keefe RS, Mohs RC, Davis KL. A study of the reliability of the family history method in genetic studies of Alzheimer disease. Alzheimer Dis Assoc Disord. 1989; 3(4):218-23.
      View in: PubMed
    248. Faull KF, Berger PA, Kilkowski J, Anderson PJ, Kraemer H, Davis KL, Barchas JD. Corrections to a 1980 article on CSF monoamine metabolites. Am J Psychiatry. 1989 Jan; 146(1):118.
      View in: PubMed
    249. Halperin R, Guerin JJ, Davis KL. Regional differences in the induction of behavioral supersensitivity by prolonged treatment with atypical neuroleptics. Psychopharmacology (Berl). 1989; 98(3):386-91.
      View in: PubMed
    250. Davis KL, Davidson M, Yang RK, Davis BM, Siever LJ, Mohs RC, Ryan T, Coccaro E, Bierer L, Targum SD. CSF somatostatin in Alzheimer's disease, depressed patients, and control subjects. Biol Psychiatry. 1988 Oct; 24(6):710-2.
      View in: PubMed
    251. Breitner JC, Murphy EA, Silverman JM, Mohs RC, Davis KL. Age-dependent expression of familial risk in Alzheimer's disease. Am J Epidemiol. 1988 Sep; 128(3):536-48.
      View in: PubMed
    252. Davidson M, Davis BM, Bastiaens L, Macaluso J, Aryan M, Ryan T, Davis KL. Growth hormone response to edrophonium in patients with Alzheimer's disease and normal control subjects. Am J Psychiatry. 1988 Aug; 145(8):1007-9.
      View in: PubMed
    253. Shutske GM, Pierrat FA, Cornfeldt ML, Szewczak MR, Huger FP, Bores GM, Haroutunian V, Davis KL. (+/-)-9-Amino-1,2,3,4-tetrahydroacridin-1-ol. A potential Alzheimer's disease therapeutic of low toxicity. J Med Chem. 1988 Jul; 31(7):1278-9.
      View in: PubMed
    254. Davidson M, Davis KL. A comparison of plasma homovanillic acid concentrations in schizophrenic patients and normal controls. Arch Gen Psychiatry. 1988 Jun; 45(6):561-3.
      View in: PubMed
    255. Coccaro EF, Siever LJ, Kourides IA, Adan F, Campbell G, Davis KL. Central serotoninergic stimulation by fenfluramine challenge does not affect plasma thyrotropin-stimulating hormone levels in man. Neuroendocrinology. 1988 Apr; 47(4):273-6.
      View in: PubMed
    256. Davidson M, Zemishlany Z, Mohs RC, Horvath TB, Powchik P, Blass JP, Davis KL. 4-Aminopyridine in the treatment of Alzheimer's disease. Biol Psychiatry. 1988 Mar 1; 23(5):485-90.
      View in: PubMed
    257. Davidson M, Bastiaens L, Davis BM, Shah MB, Davis KL. Endocrine changes in Alzheimer's disease. Endocrinol Metab Clin North Am. 1988 Mar; 17(1):149-57.
      View in: PubMed
    258. Davidson M, Bastiaens L, Davis BM, Shah MB, Davis KL. Endocrine changes in Alzheimer's disease. Neurol Clin. 1988 Feb; 6(1):149-57.
      View in: PubMed
    259. Breitner JC, Silverman JM, Mohs RC, Davis KL. Familial aggregation in Alzheimer's disease: comparison of risk among relatives of early-and late-onset cases, and among male and female relatives in successive generations. Neurology. 1988 Feb; 38(2):207-12.
      View in: PubMed
    260. Sorokin JE, Giordani B, Mohs RC, Losonczy MF, Davidson M, Siever LJ, Ryan TA, Davis KL. Memory impairment in schizophrenic patients with tardive dyskinesia. Biol Psychiatry. 1988 Jan 15; 23(2):129-35.
      View in: PubMed
    261. Davidson M, Powchik P, Davis KL. Pisa syndrome in Alzheimer's disease. Biol Psychiatry. 1988 Jan 15; 23(2):213.
      View in: PubMed
    262. Haroutunian V, Knott P, Davis KL. Effects of mesocortical dopaminergic lesions upon subcortical dopaminergic function. Psychopharmacol Bull. 1988; 24(3):341-4.
      View in: PubMed
    263. Kanof PD, Johns CA, Davidson M, Siever LJ, Coccaro EF, Davis KL. Platelet alpha 2-adrenergic receptor function in psychiatric disorders. Psychiatry Res. 1988 Jan; 23(1):11-22.
      View in: PubMed
    264. Kramer-Ginsberg E, Mohs RC, Aryan M, Lobel D, Silverman J, Davidson M, Davis KL. Clinical predictors of course for Alzheimer patients in a longitudinal study: a preliminary report. Psychopharmacol Bull. 1988; 24(3):458-62.
      View in: PubMed
    265. Keefe RS, Mohs RC, Davidson M, Losonczy MF, Silverman JM, Lesser JC, Horvath TB, Davis KL. Kraepelinian schizophrenia: a subgroup of schizophrenia? Psychopharmacol Bull. 1988; 24(1):56-61.
      View in: PubMed
    266. Friedhoff AJ, Pickar D, Axelrod J, Creese I, Davis KL, Gallagher DW, Greengard P, Housman D, Maas JW, Richelson E, et al. Neurochemistry and neuropharmacology. Schizophr Bull. 1988; 14(3):399-412.
      View in: PubMed
    267. Zemishlany Z, Davidson M, Davis KL. [Cholinergic agents in the treatment of Alzheimer's disease]. Harefuah. 1987 Dec 15; 113(12):401-4.
      View in: PubMed
    268. Davidson M, Losonczy MF, Mohs RC, Lesser JC, Powchik P, Freed LB, Davis BM, Mykytyn VV, Davis KL. Effects of debrisoquin and haloperidol on plasma homovanillic acid concentration in schizophrenic patients. Neuropsychopharmacology. 1987 Dec; 1(1):17-23.
      View in: PubMed
    269. Kanof PD, Davidson M, Johns CA, Mohs RC, Davis KL. Clinical correlates of platelet prostaglandin receptor subsensitivity in schizophrenia. Am J Psychiatry. 1987 Dec; 144(12):1556-60.
      View in: PubMed
    270. Coccaro EF, Siever LJ, Klar H, Rubenstein K, Benjamin E, Davis KL. Diminished prolactin responses to repeated fenfluramine challenge in man. Psychiatry Res. 1987 Nov; 22(3):257-9.
      View in: PubMed
    271. Silverman JM, Mohs RC, Davidson M, Losonczy MF, Keefe RS, Breitner JC, Sorokin JE, Davis KL. Familial schizophrenia and treatment response. Am J Psychiatry. 1987 Oct; 144(10):1271-6.
      View in: PubMed
    272. Hollander E, Davidson M, Mohs RC, Horvath TB, Davis BM, Zemishlany Z, Davis KL. RS 86 in the treatment of Alzheimer's disease: cognitive and biological effects. Biol Psychiatry. 1987 Sep; 22(9):1067-78.
      View in: PubMed
    273. Keefe RS, Mohs RC, Losonczy MF, Davidson M, Silverman JM, Kendler KS, Horvath TB, Nora R, Davis KL. Characteristics of very poor outcome schizophrenia. Am J Psychiatry. 1987 Jul; 144(7):889-95.
      View in: PubMed
    274. Davidson M, Keefe RS, Mohs RC, Siever LJ, Losonczy MF, Horvath TB, Davis KL. L-dopa challenge and relapse in schizophrenia. Am J Psychiatry. 1987 Jul; 144(7):934-8.
      View in: PubMed
    275. Mohs RC, Breitner JC, Silverman JM, Davis KL. Alzheimer's disease. Morbid risk among first-degree relatives approximates 50% by 90 years of age. Arch Gen Psychiatry. 1987 May; 44(5):405-8.
      View in: PubMed
    276. Weiner MF, Davis BM, Mohs RC, Davis KL. Influence of age and relative weight on cortisol suppression in normal subjects. Am J Psychiatry. 1987 May; 144(5):646-9.
      View in: PubMed
    277. Davidson M, Giordani AB, Mohs RC, Mykytyn VV, Platt S, Aryan ZS, Davis KL. Control of exogenous factors affecting plasma homovanillic acid concentration. Psychiatry Res. 1987 Apr; 20(4):307-12.
      View in: PubMed
    278. Davis KL, Hollander E, Davidson M, Davis BM, Mohs RC, Horvath TB. Induction of depression with oxotremorine in patients with Alzheimer's disease. Am J Psychiatry. 1987 Apr; 144(4):468-71.
      View in: PubMed
    279. Kanof PD, Coccaro EF, Johns CA, Siever LJ, Davis KL. Platelet [3H]imipramine binding in psychiatric disorders. Biol Psychiatry. 1987 Mar; 22(3):278-86.
      View in: PubMed
    280. Haroutunian V, Mantin R, Campbell GA, Tsuboyama GK, Davis KL. Cysteamine-induced depletion of central somatostatin-like immunoactivity: effects on behavior, learning, memory and brain neurochemistry. Brain Res. 1987 Feb 17; 403(2):234-42.
      View in: PubMed
    281. Davidson M, Giordani AB, Mohs RC, Horvath TB, Davis BM, Powchik P, Davis KL. Short-term haloperidol administration acutely elevates human plasma homovanillic acid concentration. Arch Gen Psychiatry. 1987 Feb; 44(2):189-90.
      View in: PubMed
    282. Davidson M, Mohs RC, Hollander E, Zemishlany Z, Powchik P, Ryan T, Davis KL. Lecithin and piracetam in Alzheimer's disease. Biol Psychiatry. 1987 Jan; 22(1):112-4.
      View in: PubMed
    283. Siever LJ, Coccaro EF, Zemishlany Z, Silverman J, Klar H, Losonczy MF, Davidson M, Friedman R, Mohs RC, Davis KL. Psychobiology of personality disorders: pharmacologic implications. Psychopharmacol Bull. 1987; 23(3):333-6.
      View in: PubMed
    284. Davidson M, Losonczy MF, Mohs RC, Powchick P, Freed LB, Kaminsky R, Davis KL. Effects of debrisoquin on plasma homovanillic acid concentration in schizophrenic patients. Psychopharmacol Bull. 1987; 23(3):407-10.
      View in: PubMed
    285. Davis KL, Mohs RC. Cholinergic drugs in Alzheimer's disease. N Engl J Med. 1986 Nov 13; 315(20):1286-7.
      View in: PubMed
    286. Haroutunian V, Kanof PD, Tsuboyama GK, Campbell GA, Davis KL. Animal models of Alzheimer's disease: behavior, pharmacology, transplants. Can J Neurol Sci. 1986 Nov; 13(4 Suppl):385-93.
      View in: PubMed
    287. Haroutunian V, Kanof PD, Davis KL. Partial reversal of lesion-induced deficits in cortical cholinergic markers by nerve growth factor. Brain Res. 1986 Oct 29; 386(1-2):397-9.
      View in: PubMed
    288. Silverman JM, Breitner JC, Mohs RC, Davis KL. Reliability of the family history method in genetic studies of Alzheimer's disease and related dementias. Am J Psychiatry. 1986 Oct; 143(10):1279-82.
      View in: PubMed
    289. Kanof PD, Johns C, Davidson M, Siever LJ, Coccaro EF, Davis KL. Prostaglandin receptor sensitivity in psychiatric disorders. Arch Gen Psychiatry. 1986 Oct; 43(10):987-93.
      View in: PubMed
    290. Losonczy MF, Song IS, Mohs RC, Mathé AA, Davidson M, Davis BM, Davis KL. Correlates of lateral ventricular size in chronic schizophrenia, II: biological measures. Am J Psychiatry. 1986 Sep; 143(9):1113-8.
      View in: PubMed
    291. Hollander E, Mohs RC, Davis KL. Antemortem markers of Alzheimer's disease. Neurobiol Aging. 1986 Sep-Oct; 7(5):367-407.
      View in: PubMed
    292. Losonczy MF, Song IS, Mohs RC, Small NA, Davidson M, Johns CA, Davis KL. Correlates of lateral ventricular size in chronic schizophrenia, I: Behavioral and treatment response measures. Am J Psychiatry. 1986 Aug; 143(8):976-81.
      View in: PubMed
    293. Greenwald BS, Mathé AA, Mohs RC, Levy MI, Johns CA, Davis KL. Cortisol and Alzheimer's disease, II: Dexamethasone suppression, dementia severity, and affective symptoms. Am J Psychiatry. 1986 Apr; 143(4):442-6.
      View in: PubMed
    294. Davis KL, Davis BM, Greenwald BS, Mohs RC, Mathé AA, Johns CA, Horvath TB. Cortisol and Alzheimer's disease, I: Basal studies. Am J Psychiatry. 1986 Mar; 143(3):300-5.
      View in: PubMed
    295. Davidson M, Mohs RC, Hollander E, Davis BM, Ryan T, Horvath TB, Davis KL. Physostigmine in patients with Alzheimer's disease. Psychopharmacol Bull. 1986; 22(1):101-5.
      View in: PubMed
    296. Davidson M, Kendler KS, Mohs RC, Hollander E, Ryan T, Davis KL. Effect of apomorphine infusion on plasma homovanillic acid in normal subjects. J Psychiatr Res. 1986; 20(2):131-5.
      View in: PubMed
    297. Siever LJ, Coccaro EF, Benjamin E, Rubinstein K, Davis KL. Adrenergic and serotonergic receptor responsiveness in depression. Ciba Found Symp. 1986; 123:148-63.
      View in: PubMed
    298. Hollander E, Mohs RC, Davis KL. Cholinergic approaches to the treatment of Alzheimer's disease. Br Med Bull. 1986 Jan; 42(1):97-100.
      View in: PubMed
    299. Mohs RC, Davis BM, Greenwald BS, Mathé AA, Johns CA, Horvath TB, Davis KL. Clinical studies of the cholinergic deficit in Alzheimer's disease. II. Psychopharmacologic studies. J Am Geriatr Soc. 1985 Nov; 33(11):749-57.
      View in: PubMed
    300. Davis BM, Mohs RC, Greenwald BS, Mathé AA, Johns CA, Horvath TB, Davis KL. Clinical studies of the cholinergic deficit in Alzheimer's disease. I. Neurochemical and neuroendocrine studies. J Am Geriatr Soc. 1985 Nov; 33(11):741-8.
      View in: PubMed
    301. Kendler KS, Masterson CC, Davis KL. Psychiatric illness in first-degree relatives of patients with paranoid psychosis, schizophrenia and medical illness. Br J Psychiatry. 1985 Nov; 147:524-31.
      View in: PubMed
    302. Davidson M, Kendler KS, Davis BM, Horvath TB, Mohs RC, Davis KL. Apomorphine has no effect on plasma homovanillic acid in schizophrenic patients. Psychiatry Res. 1985 Oct; 16(2):95-9.
      View in: PubMed
    303. Haroutunian V, Kanof P, Davis KL. Pharmacological alleviation of cholinergic lesion induced memory deficits in rats. Life Sci. 1985 Sep 9; 37(10):945-52.
      View in: PubMed
    304. Siever LJ, Davis KL. Overview: toward a dysregulation hypothesis of depression. Am J Psychiatry. 1985 Sep; 142(9):1017-31.
      View in: PubMed
    305. Mohs RC, Davis KL. Interaction of choline and scopolamine in human memory. Life Sci. 1985 Jul 15; 37(2):193-7.
      View in: PubMed
    306. Deutsch SI, Halperin R, Stanley M, Davis KL. Effect of chronic haloperidol and quinacrine coadministration on striatal HVA levels and stereotypic behaviors in response to apomorphine in the rat. Neurochem Res. 1985 Apr; 10(4):491-8.
      View in: PubMed
    307. Kanof PD, Greenwald BS, Mohs RC, Davis KL. Red blood cell choline. II: Kinetics in Alzheimer's disease. Biol Psychiatry. 1985 Apr; 20(4):375-83.
      View in: PubMed
    308. Greenwald BS, Edasery J, Mohs RC, Shah N, Trigos GG, Davis KL. Red blood cell choline. I: Choline in Alzheimer's disease. Biol Psychiatry. 1985 Apr; 20(4):367-74.
      View in: PubMed
    309. Davis KL, Davidson M, Mohs RC, Kendler KS, Davis BM, Johns CA, DeNigris Y, Horvath TB. Plasma homovanillic acid concentration and the severity of schizophrenic illness. Science. 1985 Mar 29; 227(4694):1601-2.
      View in: PubMed
    310. Davis BM, Davis KL, Mohs RC, Mathé AA, Rothpearl AB, Johns CA, Levy MI, Horvath TB. Evaluating prolactin response to dopamine agonists in schizophrenia. Methodological problems. Arch Gen Psychiatry. 1985 Mar; 42(3):259-64.
      View in: PubMed
    311. Schleifer SJ, Keller SE, Siris SG, Davis KL, Stein M. Depression and immunity. Lymphocyte function in ambulatory depressed patients, hospitalized schizophrenic patients, and patients hospitalized for herniorrhaphy. Arch Gen Psychiatry. 1985 Feb; 42(2):129-33.
      View in: PubMed
    312. Mohs RC, Davis BM, Johns CA, Mathé AA, Greenwald BS, Horvath TB, Davis KL. Oral physostigmine treatment of patients with Alzheimer's disease. Am J Psychiatry. 1985 Jan; 142(1):28-33.
      View in: PubMed
    313. Haroutunian V, Barnes E, Davis KL. Cholinergic modulation of memory in rats. Psychopharmacology (Berl). 1985; 87(3):266-71.
      View in: PubMed
    314. Rosen WG, Mohs RC, Johns CA, Small NS, Kendler KS, Horvath TB, Davis KL. Positive and negative symptoms in schizophrenia. Psychiatry Res. 1984 Dec; 13(4):277-84.
      View in: PubMed
    315. Rosen WG, Mohs RC, Davis KL. A new rating scale for Alzheimer's disease. Am J Psychiatry. 1984 Nov; 141(11):1356-64.
      View in: PubMed
    316. Kendler KS, Davis KL. Acute and chronic effects of neuroleptic drugs on plasma and brain homovanillic acid in the rat. Psychiatry Res. 1984 Sep; 13(1):51-8.
      View in: PubMed
    317. Davis KL, Davis BM, Mathé AA, Mohs RC, Rothpearl AB, Levy MI, Gorman LK, Berger P. Age and the dexamethasone suppression test in depression. Am J Psychiatry. 1984 Jul; 141(7):872-4.
      View in: PubMed
    318. Losonczy MF, Mohs RC, Davis KL. Seasonal variations of human lumbar CSF neurotransmitter metabolite concentrations. Psychiatry Res. 1984 May; 12(1):79-87.
      View in: PubMed
    319. Levy MI, Davis BM, Mohs RC, Kendler KS, Mathé AA, Trigos G, Horvath TB, Davis KL. Apomorphine and schizophrenia. Treatment, CSF, and neuroendocrine responses. Arch Gen Psychiatry. 1984 May; 41(5):520-4.
      View in: PubMed
    320. Schleifer SJ, Keller SE, Meyerson AT, Raskin MJ, Davis KL, Stein M. Lymphocyte function in major depressive disorder. Arch Gen Psychiatry. 1984 May; 41(5):484-6.
      View in: PubMed
    321. Fiori M, Davis KL. Possible clinical applications of laboratory tests in depression. J Clin Psychiatry. 1984 Apr; 45(4 Pt 2):6-11.
      View in: PubMed
    322. Kendler KS, Masterson CC, Ungaro R, Davis KL. A family history study of schizophrenia-related personality disorders. Am J Psychiatry. 1984 Mar; 141(3):424-7.
      View in: PubMed
    323. Kendler KS, Davis KL. Genetic control of apomorphine-induced climbing behavior in two inbred mouse strains. Brain Res. 1984 Feb 20; 293(2):343-51.
      View in: PubMed
    324. Small NE, Mohs RC, Halperin R, Rosen WG, Masterson C, Kendler KS, Horvath TB, Davis KL. A study of the reliability of reported premorbid adjustment in schizophrenic patients. Biol Psychiatry. 1984 Feb; 19(2):203-11.
      View in: PubMed
    325. Siever LJ, Davis KL. Dysregulation of the noradrenergic system in depression. Psychopharmacol Bull. 1984; 20(3):500-4.
      View in: PubMed
    326. Johns CA, Levy MI, Davis BM, Mohs RC, Kendler KS, Mathe AA, Trigos G, Horvath TB, Davis KL. Apomorphine and schizophrenia. Psychopharmacol Bull. 1984; 20(1):103-7.
      View in: PubMed
    327. Deutsch SI, Mohs RC, Levy MI, Rothpearl AB, Stockton D, Horvath T, Coco A, Davis KL. Acetylcholinesterase activity in CSF in schizophrenia, depression, Alzheimer's disease and normals. Biol Psychiatry. 1983 Dec; 18(12):1363-73.
      View in: PubMed
    328. Halperin R, Guerin JJ, Davis KL. Chronic administration of three neuroleptics: effects of behavioral supersensitivity mediated by two different brain regions in the rat. Life Sci. 1983 Aug 8; 33(6):585-92.
      View in: PubMed
    329. Levy MI, Kendler KS, Mathé AA, Mohs RC, Denigris Y, Trigos GG, Axiotis A, Rothpearl A, Davis KL. Antipsychotic efficacy of fluotracen: a clinical trial. J Clin Psychopharmacol. 1983 Jun; 3(3):189-92.
      View in: PubMed
    330. Hsieh JY, Yang RK, Davis KL. High-performance liquid chromatographic determination of tetrahydroaminoacridine in human and rat tissues using a rapid Sep-Pak C18 extraction. J Chromatogr. 1983 May 13; 274:388-92.
      View in: PubMed
    331. Deutsch SI, Davis KL. Schizophrenia: a review of diagnostic and biological issues. II. Biological issues. Hosp Community Psychiatry. 1983 May; 34(5):423-37.
      View in: PubMed
    332. Greenwald BS, Mohs RC, Davis KL. Neurotransmitter deficits in Alzheimer's disease: criteria for significance. J Am Geriatr Soc. 1983 May; 31(5):310-6.
      View in: PubMed
    333. Levy MI, Davis BM, Mohs RC, Trigos GC, Mathé AA, Davis KL. Gamma-hydroxybutyrate in the treatment of schizophrenia. Psychiatry Res. 1983 May; 9(1):1-8.
      View in: PubMed
    334. Deutsch SI, Davis KL. Schizophrenia: a review of diagnostic and biological issues. I. Diagnosis and prognosis. Hosp Community Psychiatry. 1983 Apr; 34(4):313-22.
      View in: PubMed
    335. Kendler KS, Mohs RC, Davis KL. The effects of diet and physical activity on plasma homovanillic acid in normal human subjects. Psychiatry Res. 1983 Mar; 8(3):215-23.
      View in: PubMed
    336. Pepper GM, Davis KL, Davis BM, Krieger DT. DST in depression is unaffected by altering the clock time of its administration. Psychiatry Res. 1983 Feb; 8(2):105-9.
      View in: PubMed
    337. Greenwald BS, Davis KL. Experimental pharmacology of Alzheimer disease. Adv Neurol. 1983; 38:87-102.
      View in: PubMed
    338. Hsieh JY, Yang RK, Davis KL. Improved sample preparation before liquid-chromatographic determination of probenecid in cerebrospinal fluid. Clin Chem. 1983 Jan; 29(1):213-4.
      View in: PubMed
    339. Johns CA, Greenwald BS, Mohs RC, Davis KL. The cholinergic treatment strategy in aging and senile dementia. Psychopharmacol Bull. 1983; 19(2):185-97.
      View in: PubMed
    340. Davis KL, Mohs RC, Davis BM, Horvath TB, Greenwald BS, Rosen WG, Levy MI, Johns CA. Oral physostigmine in Alzheimer's disease. Psychopharmacol Bull. 1983; 19(3):451-3.
      View in: PubMed
    341. Davis BM, Mathé AA, Mohs RC, Levy MI, Davis KL. Effects of propantheline bromide on basal growth hormone, cortisol and prolactin levels. Psychoneuroendocrinology. 1983; 8(1):103-7.
      View in: PubMed
    342. Mohs RC, Rosen WG, Davis KL. The Alzheimer's disease assessment scale: an instrument for assessing treatment efficacy. Psychopharmacol Bull. 1983; 19(3):448-50.
      View in: PubMed
    343. Davis KL, Mohs RC. Enhancement of memory processes in Alzheimer's disease with multiple-dose intravenous physostigmine. Am J Psychiatry. 1982 Nov; 139(11):1421-4.
      View in: PubMed
    344. Stahl SM, Davis KL, Berger PA. The neuropharmacology of tardive dyskinesia, spontaneous dyskinesia, and other dystonias. J Clin Psychopharmacol. 1982 Oct; 2(5):321-8.
      View in: PubMed
    345. Davis KL, Hsieh JY, Levy MI, Horvath TB, Davis BM, Mohs RC. Cerebrospinal fluid acetylcholine, choline, and senile dementia of the Alzheimer's type. Psychopharmacol Bull. 1982 Oct; 18(4):193-5.
      View in: PubMed
    346. Kendler KS, Hsieh JY, Davis KL. Studies of plasma homovanillic acid as an index of brain dopamine function. Psychopharmacol Bull. 1982 Oct; 18(4):152-5.
      View in: PubMed
    347. Rosenberg GS, Davis KL. The use of cholinergic precursors in neuropsychiatric diseases. Am J Clin Nutr. 1982 Oct; 36(4):709-20.
      View in: PubMed
    348. Mohs RC, Davis BM, Rosenberg GS, Davis KL, Krieger DT. Naloxone does not affect pain sensitivity, mood or cognition in patients with high levels of beta-endorphin in plasma. Life Sci. 1982 May 24; 30(21):1827-33.
      View in: PubMed
    349. Kendler KS, Bracha HS, Davis KL. Dopamine autoreceptor and postsynaptic receptor blocking potency of neuroleptics. Eur J Pharmacol. 1982 Apr 23; 79(3-4):217-23.
      View in: PubMed
    350. Levy MI, DeNigris Y, Davis KL. Rapid antidepressant activity of melanocyte-inhibiting factor: a clinical trial. Biol Psychiatry. 1982 Feb; 17(2):259-63.
      View in: PubMed
    351. Mohs RC, Davis KL. A signal detectability analysis of the effect of physostigmine on memory in patients with Alzheimer's disease. Neurobiol Aging. 1982; 3(2):105-10.
      View in: PubMed
    352. Deutsch SI, Mohs RC, Davis KL. A rationale for studying the transmissibility of Alzheimer's disease. Neurobiol Aging. 1982; 3(2):145-7.
      View in: PubMed
    353. Davis BM, Brown GM, Miller M, Friesen HG, Kastin AJ, Davis KL. Effects of cholinergic stimulation on pituitary hormone release. Psychoneuroendocrinology. 1982; 7(4):347-54.
      View in: PubMed
    354. Levy MI, Mohs RC, Rosen WG, Davis KL. Research subject recruitment for gerontological studies of pharmacological agents. Neurobiol Aging. 1982; 3(1):77-9.
      View in: PubMed
    355. Rothpearl AB, Mohs RC, Davis KL. Statistical power in biological psychiatry. Psychiatry Res. 1981 Dec; 5(3):257-66.
      View in: PubMed
    356. Davis KL, Hollister LE, Mathé AA, Davis BM, Rothpearl AB, Faull KF, Hsieh JY, Barchas JD, Berger PA. Neuroendocrine and neurochemical measurements in depression. Am J Psychiatry. 1981 Dec; 138(12):1555-62.
      View in: PubMed
    357. Mohs RC, Davis KL, Levy MI. Partial reversal of anticholinergic amnesia by choline chloride. Life Sci. 1981 Sep 28; 29(13):1317-23.
      View in: PubMed
    358. Murphy MF, Davis KL. Biological perspectives in chronic pain, depression, and organic mental disorders. Psychiatr Clin North Am. 1981 Aug; 4(2):223-37.
      View in: PubMed
    359. Davis KL, Samuel A, Mathé AA, Mohs RC. Intracerebral des-tyrosine-gamma-endorphin inhibits methylphenidate induced locomotor activity. Life Sci. 1981 May 21; 28(21):2421-4.
      View in: PubMed
    360. Davis KL, Rosenberg GS. Induction of behavioral supersensitivity to apomorphine by DFP treatment. Life Sci. 1981 Apr 27; 28(17):1953-9.
      View in: PubMed
    361. Davis BM, Pfefferbaum A, Krutzik S, Davis KL. Lithium's effect of parathyroid hormone. Am J Psychiatry. 1981 Apr; 138(4):489-92.
      View in: PubMed
    362. Kendler KS, Davis KL. The genetics and biochemistry of paranoid schizophrenia and other paranoid psychoses. Schizophr Bull. 1981; 7(4):689-709.
      View in: PubMed
    363. Davis KL, Faull KF, Hollister LE, Barchas JD, Berger PA. Alterations in cerebrospinal fluid dopamine metabolites following physostigmine infusion. Psychopharmacology (Berl). 1981; 72(2):155-60.
      View in: PubMed
    364. Hollister LE, Davis KL, Berger PA. Subtypes of depression based on excretion of MHPG and response to nortriptyline. Arch Gen Psychiatry. 1980 Oct; 37(10):1107-10.
      View in: PubMed
    365. Davis KL, Mohs RC, Davis BM, Horvath TB, Tinklenberg JR, Rosenberg GS, Levy MI. Human memory and the effects of physostigmine and choline chloride [proceedings]. Psychopharmacol Bull. 1980 Oct; 16(4):27-8.
      View in: PubMed
    366. Davis KL, Kastin AJ, Beilstein BA, Vento AL. MSH and MIF-I in animal models of tardive dyskinesia. Pharmacol Biochem Behav. 1980 Jul; 13(1):37-40.
      View in: PubMed
    367. Berger PA, Watson SJ, Akil H, Elliott GR, Rubin RT, Pfefferbaum A, Davis KL, Barchas JD, Li CH. beta-Endorphin and schizophrenia. Arch Gen Psychiatry. 1980 Jun; 37(6):635-40.
      View in: PubMed
    368. Mohs RC, Davis KL. Choline chloride effects on memory: correlation with the effects of physostigmine. Psychiatry Res. 1980 May; 2(2):149-56.
      View in: PubMed
    369. Hollister LE, Pfefferbaum A, Davis KL. Monitoring nortriptyline plasma concentrations. Am J Psychiatry. 1980 Apr; 137(4):485-6.
      View in: PubMed
    370. Davis BM, Davis KL. CKholinergic mechanisms and anterior pituitary hormone secretion. Biol Psychiatry. 1980 Apr; 15(2):303-10.
      View in: PubMed
    371. Berger PA, Faull KF, Kilkowski J, Anderson PJ, Kraemer H, Davis KL, Barchas JD. CSF monoamine metabolites in depression and schizophrenia. Am J Psychiatry. 1980 Feb; 137(2):174-80.
      View in: PubMed
    372. Mohs RC, Davis KL, Tinklenberg JR, Hollister LE. Choline chloride effects on memory in the elderly. Neurobiol Aging. 1980; 1(1):21-5.
      View in: PubMed
    373. Davis KL, Mohs RC, Tinklenberg JR, Hollister LE, Pfefferbaum A, Kopell BS. Cholinomimetics and memory. The effect of choline chloride. Arch Neurol. 1980 Jan; 37(1):49-52.
      View in: PubMed
    374. Hollister LE, Davis KL, Berger PA. Apomorphine in schizophrenia. Commun Psychopharmacol. 1980; 4(4):277-81.
      View in: PubMed
    375. Davis KL, Hollister LE, Berger PA. Choline chloride in schizophrenia. Am J Psychiatry. 1979 Dec; 136(12):1581-4.
      View in: PubMed
    376. Davis KL, Mohs RC, Tinklenberg JR. Enhancement of memory by physostigmine. N Engl J Med. 1979 Oct 25; 301(17):946.
      View in: PubMed
    377. Mohs RC, Davis KL, Tinklenberg JR, Hollister LE, Yesavage JA, Kopell BS. Choline chloride treatment of memory deficits in the elderly. Am J Psychiatry. 1979 Oct; 136(10):1275-7.
      View in: PubMed
    378. Davis KL. Cholinomimetic treatment of neuropsychiatric disorders: a review of recent developments. Mt Sinai J Med. 1979 Sep-Oct; 46(5):455-9.
      View in: PubMed
    379. Davis KL, Rosenberg GS. Is there a limbic system equivalent of tardive dyskinesia? Biol Psychiatry. 1979 Aug; 14(4):699-703.
      View in: PubMed
    380. Davis KL, Hollister LE, Livesey J, Berger PA. Cerebrospinal fluid acetylcholinesterase in neuropsychiatric disorders. Psychopharmacology (Berl). 1979 May 25; 63(2):155-9.
      View in: PubMed
    381. Pfefferbaum A, Davis KL, Coulter CL, Mohs RC, Tinklenberg JR, Kopell BS. EEG effects of physostigmine and choline chloride in humans. Psychopharmacology (Berl). 1979 Apr 25; 62(3):225-33.
      View in: PubMed
    382. Hollister LE, Davis KL, Overall JE, Anderson T. Excretion of MHPG in normal subjects: implications for biological classification of affective disorders. Arch Gen Psychiatry. 1978 Dec; 35(12):1410-5.
      View in: PubMed
    383. Davis KL, Yamamura HI. Cholinergic underactivity in human memory disorders. Life Sci. 1978 Oct 30; 23(17-18):1729-33.
      View in: PubMed
    384. Davis KL, Hollister LE, Fritz WC. Induction of dopaminergic mesolimbic receptor supersensitivity by haloperidol. Life Sci. 1978 Oct 16; 23(15):1543-8.
      View in: PubMed
    385. Davis KL, Hollister LE, Berger PA, Vento AL. Studies on choline chloride in neuropsychiatric disease: human and animal data. Psychopharmacol Bull. 1978 Oct; 14(4):56-8.
      View in: PubMed
    386. Davis KL, Mohs RC, Tinklenberg JR, Pfefferbaum A, Hollister LE, Kopell BS. Physostigmine: improvement of long-term memory processes in normal humans. Science. 1978 Jul 21; 201(4352):272-4.
      View in: PubMed
    387. Hollister LE, Jenden DJ, Amaral JR, Barchas JD, Davis KL, Berger PA. Plasma concentrations of choline in man following choline chloride. Life Sci. 1978 Jul 3; 23(1):17-22.
      View in: PubMed
    388. Davis KL, Berger PA, Hollister LE, Barchas JD. Cholinergic involvement in mental disorders. Life Sci. 1978 Jun 5; 22(21):1865-71.
      View in: PubMed
    389. Davis KL, Hollister LE, Vento AL, Simonton S. Choline chloride in animal models of tardive dyskinesia. Life Sci. 1978 May 15; 22(19):1699-707.
      View in: PubMed
    390. Davis KL, Berger PA. Pharmacological investigations of the cholinergic imbalance hypotheses of movement disorders and psychosis. Biol Psychiatry. 1978 Feb; 13(1):23-49.
      View in: PubMed
    391. Davis KL, Berger PA, Hollister LE, Defraites E. Physostigmine in mania. Arch Gen Psychiatry. 1978 Jan; 35(1):119-22.
      View in: PubMed
    392. Wermuth BM, Davis KL, Hollister LE, Stunkard AJ. Phenytoin treatment of the binge-eating syndrome. Am J Psychiatry. 1977 Nov; 134(11):1249-53.
      View in: PubMed
    393. Davis KL, Hollister LE, Goodwin FK, Gordon EK. Neurotransmitter metabolites in the cerebrospinal fluid of man following physostigmine. Life Sci. 1977 Oct 1; 21(7):933-6.
      View in: PubMed
    394. Atsaides JP, Neuringer C, Davis KL. Development of an Institutionalized Chronic Alcoholic Scale. J Consult Clin Psychol. 1977 Aug; 45(4):609-11.
      View in: PubMed
    395. Davis KL, Berger PA, Hollister LE. Deanol in tardive dyskinesia. Am J Psychiatry. 1977 Jul; 134(7):807.
      View in: PubMed
    396. Davis KL, Estess FM, Simonton SC, Gonda TA. Effects of payment mode on clinic attendance and rehospitalization. Am J Psychiatry. 1977 May; 134(5):576-8.
      View in: PubMed
    397. De Fraites EG, Davis KL, Berger PA. Coexisting tardive dyskinesia and parkinsonism: a case report. Biol Psychiatry. 1977 Apr; 12(2):267-72.
      View in: PubMed
    398. Davis KL, Hollister LE, Overall J, Johnson A, Train K. Physostigmine: effects on cognition and affect in normal subjects. Psychopharmacology (Berl). 1976 Dec 21; 51(1):23-7.
      View in: PubMed
    399. Hollister LE, Davis KL, Berger PA. Pituitary response to thyrotropin-releasing hormone in depression. Arch Gen Psychiatry. 1976 Nov; 33(11):1393-96.
      View in: PubMed
    400. Davis KL, Berger PA, Hollister LE. Tardive dyskinesia and depressive illness. Psychopharmacol Commun. 1976; 2(2):125-30.
      View in: PubMed
    401. Davis KL, Hossister LE, Berger PA. Thyrotropin-releasing hormone in schizophrenia. Am J Psychiatry. 1975 Sep; 132(9):951-3.
      View in: PubMed
    402. Davis KL, Hollister LE, Berger PA, Barchas JD. Cholinergic imbalance hypotheses of psychoses and movement disorders: strategies for evaluation. Psychopharmacol Commun. 1975; 1(5):533-43.
      View in: PubMed
    403. Hollister LE, Davis KL, Berger PA. Butaclamol hydrochloride in newly admitted schizophrenics. Psychopharmacol Commun. 1975; 1(5):493-500.
      View in: PubMed
    404. Davis KL, Qualls B, Hollister L, Stunkard AJ. Letter: EEGs of "binge" eaters. Am J Psychiatry. 1974 Dec; 131(12):1409.
      View in: PubMed
    Davis's Networks
    Click the "See All" links for more information and interactive visualizations!
    Concepts
    _
    Co-Authors
    _
    Similar People
    _
     
    Mount Sinai Profiles is managed by Conduits - The Institutes for Translational Sciences at Icahn School of Medicine, supported by the National Center for Research Resources and the National Center for Advancing Translational Sciences of the National Institutes of Health through Grant Number UL1TR000067